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Abstract 
Despite the importance of integrins in epithelial cell biology surprisingly little is 
known about their regulation. It is known that they form hemidesmosomes (HDs), are 
actively involved in cell contacts during cell migration/invasion, and are key signaling 
molecules for survival and growth. However, there has been a distinct lack of 
understanding about what controls the dynamic integrin localization during cell activation 
and movement. Growth factors, such as EGF, are elevated during wound healing and 
carcinoma invasion leading to phosphorylation of ITGβ4 and the disassembly of the HD 
and mobilization of ITGβ4 to actin-rich protrusions. More recently the phosphorylation 
of a novel site on ITGβ4 (S1424) was found to be distinctly enriched on the trailing edge 
of migrating cells, suggesting a possible mechanism for the dissociation of ITGβ4 from 
HDs.  
Arrestin family member proteins are involved in the regulation of cell surface 
proteins and vesicular trafficking. In this study, we find that over-expression of arrestin 
family member ARRDC3 causes internalization and proteosome-dependent degradation 
of ITGβ4, while decreased levels of ARRDC3 stabilizes ITGβ4 levels. These results lead 
us to a new mechanism of ITGβ4 internalization, trafficking and degradation. During 
migration, ARRDC3 co-localizes with ITGβ4 on the lagging edge of cells but has a 
distinct distribution on the leading edge of cells. Additional immuno co-precipitation 
experiments demonstrate that ARRDC3 preferentially binds to ITGβ4 when 
phosphorylated on S1424. Using confocal microscopy, we show that the expression 
pattern of ARRDC3 on the lagging edge of a migrating cell is identical to the expression 
 viii
pattern of ITGβ4-pS1424. We demonstrate that ARRDC3 expression represses cell 
proliferation, migration, invasion, growth in soft agar and tumorigenicity.  
Collectively, our data reveals that ARRDC3 is a negative regulator of β4 integrin 
and demonstrates how this new pathway impacts biologic processes in stem cell and 
cancer biology. Additionally, as ARRDC3 is highly expressed in several tissues and 
conserved across species, our results are likely to be translated to other models.
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CHAPTER I: 
Introduction 
 2
Adult Stem Cells  
An adult stem cell, also termed somatic stem cell or tissue specific stem cell, is 
defined as an undifferentiated cell, found among differentiated cells in a tissue or organ, 
that can self-renew and differentiate to yield some or all of the major specialized cell 
types of the tissue or organ (Evans and Potten, 1991; Moore and Lemischka, 2006; 
Morasso and Tomic-Canic, 2005). The primary role of adult stem cells in a living 
organism is to maintain and repair the tissue in which they are found. Unlike embryonic 
stem cells, which are defined by their origin (the inner cell mass of the blastocyst), the 
origin of adult stem cells in most mature tissues is still under investigation. Adult stem 
cells have two general properties: they are capable of long-term self-renewal and they are 
undifferentiated (Morrison and Spradling, 2008; Potten and Morris, 1988). However, 
whereas embryonic stem cells are considered to be pluripotent and therefore capable of 
differentiation into almost all cells from the three germ layers; adult stem cells are multi-
potent and only capable of producing a limited range of differentiated cells, typically 
confined to those of a single tissue (Morrison and Spradling, 2008; Potten and Morris, 
1988). 
Functions of Adult Stem Cells 
Adult stem cells are identified as the cells responsible for the regeneration of the 
tissues in which they reside. They are generally considered to be capable of 
differentiating into the multiple cell types within the tissue in which they reside 
(Spradling et al., 2001). This is vital in the overall homeostasis of the tissue as well as 
injury repair. In order for stem cells to fulfill these critical functions, they have to 
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maintain several properties. Upon division, stem cells need to maintain the stem cell pool 
(self-renewal) as well as derive more differentiated cells.  This is generally believed to be 
accomplished through asymmetrical cell division, in which one daughter cell retains the 
stem cell characteristics while the other daughter cell continues down a path of 
hierarchical differentiation. However, current data does not conclusively exclude other 
mechanisms, such as interspersed divisions of stem cells resulting in either self-renewal 
or differentiation. Stem cells are generally slow-cycling in-vivo but give rise to highly 
proliferative transit-amplifying cells, the cells which ultimately differentiate to replenish 
lost cells (Potten, 1974; Potten et al., 1974). This system is believed to minimize the 
number of times the stem cell needs to undergo DNA synthesis, thus limiting the 
introduction of mutations. 
Stem Cell Niche 
 Due to the essential role of adult stem cells in tissue regeneration and wound 
repair, the proper upkeep of these cells is crucial. Maintenance is thought to be achieved 
through the interactions between the stem cells and their specialized microenvironment 
known as the niche, first postulated by Schofield in 1978 (Schofield, 1978). Stem cell 
functions (i.e. the balance between self-renewal and differentiation) are primarily 
controlled by extracellular cues from the niche, although the natures of many of these 
signals are still unclear. Comparison of the most understood stem cell niches (mammalian 
bone marrow, skin, intestine and testis) reveals several common properties (reviewed in 
(Li and Xie, 2005; Moore and Lemischka, 2006)). The niche is typically an asymmetric 
structure; cells supporting the undifferentiated state are located on one end with cells 
 4
promoting differentiation on the other. This asymmetry likely helps to ensure the 
asymmetric division of the stem cells.  Also, stem cells will tightly adhere themselves 
within the niche by increasing expression of adhesion molecules such as cadherins and 
integrins. Strong adherence makes it difficult for physical damage to dislodge the adult 
stem cells from their protective environment. Additionally, all known niches contain a 
variety of support cells that are essential in producing extrinsic factors, which both 
positively and negatively regulate the growth-restrictive and un-differentiated state. The 
loss of the niche has severe consequences. Excessive self renewal at the expense of 
differentiation leads to aberrant expansion and even tumorigenesis as well as 
degeneration of the tissue. Conversely, excessive differentiation at the expense of self-
renewal will deplete the stem cell pool leading to a reduction in the regenerative capacity 
of tissues, affecting both normal homeostasis as well as wound healing. 
The Epidermis & Skin Stem Cells 
The mammalian skin represents a physical barrier between the body and its 
external environment, receiving most of the damage brought on by physical trauma and 
mutagenic UV radiation. The skin is a multi-layered epithelium that is comprised of 
sebaceous glands, hair follicles and the interfollicular epidermis.  In order to protect 
against the accumulation of mutations, the epidermis has a rapid cellular turnover, 
renewing itself in humans every 2-3 weeks (Potten, 1975a; Potten, 1975b). This 
regeneration is sustained by different populations of epidermal stem cells which 
additionally participate in the repair of the skin after injuries. These cells are quiescent 
but upon injury can be mobilized into an extensive and sustained self-renewal capacity. 
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 There are two main methods used to identify epidermal stem cells. The first 
makes use of the slow-cycling nature that defines all stem cells in a pulse-chase assay. 
Actively proliferating cells are pulse-labeled with the introduction of a DNA precursor 
like 3H-TdR or BrdU. For in-vivo studies, mice are injected at post-natal day 3 or shortly 
after the engraftment of human skin onto an adult nude mouse. The DNA precursor can 
be added into the media for in-vitro studies. The labeling period is then followed by an 
extended chase period (4-10 weeks); proliferating cells will dilute the label by half with 
every cell division.  Over time, the rapidly proliferating cells, such as the transit 
amplifying cells, will no longer contain detectable levels of label but the stem cells will 
(Bickenbach and Mackenzie, 1984; Braun et al., 2003; Cotsarelis et al., 1990). Inducible 
GFP and β-galactosidase have also been used as pulse-labeling reagents in adapted 
methods (Tumbar et al., 2004). The second method used for identification of epidermal 
stem cells involves the use of stem cell markers. Current markers include ITGα6, ITGβ1, 
CD71lo, CD34, CD200, KRT15 and KRT19 (Cotsarelis, 2006; Jih et al., 1999; Lyle et al., 
1998; Lyle et al., 1999; Trempus et al., 2003; Van Waes et al., 1991). Unfortunately, 
most of the markers identified lack specificity to epidermal stem cells alone. However, 
these markers in combination with knowledge of the approximate physical location 
relative to histological markers will allow for accurate isolation through micro-dissection 
and laser capture. A combination of cell labeling and immuno-marking techniques 
identified epidermal stem cells located in the hair follicle bulge as well as within the 
interfollicular region of the skin. 
The Hair Follicle Bulge 
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The bulge region of the hair follicle represents the best characterized epidermal 
stem cell population described to date, but there is evidence of other stem populations in 
the interfollicular epidermis and the sebaceous glands (Bieniek et al., 2007; Kaur, 2006; 
Tiede et al., 2007). In human fetal  and murine follicles, the bulge is a morphologically 
prominent outgrowth of epithelial cells below the opening of the sebaceous gland, 
marking the lower end of the permanent portion of the follicle (Akiyama et al., 1995). In 
contrast, this morphological structure is not typically seen in adult human follicles (only 
at the onset of anagen) and therefore the location of the bulge is estimated to be roughly 
located at the insertion of the arrector pili muscle (Figure 1-1). These bulge cells have 
been demonstrated to possess stem cell properties in-vivo and in-vitro (Cotsarelis et al., 
1990; Kobayashi et al., 1993). In addition to the in-vitro studies, the bulge cells possess 
the in-vivo proliferative behavior expected of stem cells. While the stem cells are 
generally slowly cycling, as determined in label-retaining studies, cell proliferation 
analysis shows that the stem cells of the mouse bulge are activated to transiently 
proliferate at the onset of anagen (Wilson et al., 1994) starting the hair cycle as 
characterized in the “bulge activation hypothesis” (Cotsarelis et al., 1990). 
 Similar to other epithelial tissues (Cotsarelis et al., 1989; Lavker and Sun, 1982) 
the bulge has all the features expected of a stem cell niche and the bulge cells display the 
characteristics of stem cells. The bulge represents the permanent portion of the hair 
follicle; while the lower follicle undergoes apoptosis and degenerates during catagen. 
Bulge cells are tightly adherent to the basement membrane and are protected from 
accidental loss to plucking (Cotsarelis et al., 1990). Plucking of human follicles, which 
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can remove a majority of the hair follicle epithelium below the level of the bulge, will 
still result in hair regeneration (Moll, 1995).  The basement membrane zone of the bulge 
also appears specialized for its role in protecting the bulge cells. K-laminin and type VII 
collagen are much more highly expressed in the basement membrane zone of the bulge 
than in the lower portion of the outer root sheath (ORS), allowing for increased adhesion  
to the niche (Akiyama et al., 1995). Additionally, the vasculature of the bulge provides 
nourishment for this important area and the bulge-containing isthmus region is the most 
richly innervated skin area (Schneider et al., 2009). The bulge area also contains a 
concentrated number of Langerhans cells, a cell type thought to help maintain the 
epidermal stem cell niche (Allen and Potten, 1974; Potten and Allen, 1976).  
There are three major epithelial cell types in which bulge cells can contribute: 
sebaceous glands, epidermis and the whole hair follicle. Bulge cells are primarily 
responsible for the regeneration of a new lower follicle and the start a new hair cycle (Liu 
et al., 2003; Lyle et al., 1998; Oshima et al., 2001). In addition, these cells can contribute 
to the sebaceous gland and epidermis as well (Ito et al., 2005; Morris et al., 2004; Oshima 
et al., 2001). The main role for inter-follicular (IF) stem cells seems to be replenishing the 
inter-follicular epidermis (IFE); however these cells are capable of giving rise to cells of 
multiple lineages including the hair (Ferraris et al., 1997; Reynolds and Jahoda, 1992; 
Silva-Vargas et al., 2005). It is likely that during normal tissue homeostasis, both inter-
follicular and bulge stem cells respond to niche derived signals and give rise to restricted 
subsets of progeny (Ferraris et al., 1997; Niemann et al., 2002). However, after an event  
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that disrupts normal tissue homeostasis (such as wounding or engraftment), all epidermal 
stem cells may be stimulated to produce daughter cells of all the epidermal lineages 
(Blanpain et al., 2004; Ito et al., 2005; Morris et al., 2004; Tumbar et al., 2004). 
Skin Stem Cell Signaling Pathways 
There are several signaling pathways critical in the regulation of bulge stem cells, 
but the Wnt/β-catenin pathway is perhaps the best characterized. Repressing this pathway 
with dominant negative forms of either β-catenin or the downstream transcription factor 
Lef1 results in the loss of hair follicles and formation of cysts of IFE with associated 
sebocytes (Huelsken et al., 2001; Zhu and Watt, 1999). Additionally, mice expressing 
either dominant negative β-catenin or dominant negative Lef1 can form sebaceous and 
hair tumors (trichofolliculomas and pilomatricomas) (Huelsken et al., 2001; Takeda et al., 
2006). Conversely, constitutively active β-catenin or Lef1 results in de novo hair 
morphogenesis at the expense of sebaceous differentiation (Gat et al., 1998; Huelsken et 
al., 2001; Zhu and Watt, 1999).  Activation of β-catenin can additionally induce bulge 
stem cells to re-enter the cell cycle in a Hedgehog (Hh) dependent manner (Lowry et al., 
2005; Niemann, 2006).  
Hh signaling is also important for lineage determination of bulge stem cells. 
Where Sonic Hh (SHH) has been shown to be important for hair follicle development and 
basal cell carcinogenesis, Indian Hh (IHH) is involved in the growth and differentiation 
of sebocytes in normal skin and in the formation of sebaceous tumors of human and mice 
(Adolphe et al., 2004; Niemann et al., 2003).  
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The appropriate timing of c-Myc expression is also important for the self-
renewal/differentiation balance. When c-Myc is mis-expressed in bulge stem cells, they 
will aberrantly differentiate into inter-follicular epidermis and sebocytes (Arnold and 
Watt, 2001; Waikel et al., 2001). However, it is believed that c-Myc actually regulates 
the departure of the bulge stem cells from their niche, and it is the absence of the 
restrictive environment that subsequently causes proliferation and differentiation (Frye et 
al., 2007; Watt et al., 2008).  
Finally, bone morphogenic protein (BMP) signaling is critical in maintaining the 
quiescence of the bulge stem cells (Andl et al., 2004; Kobielak et al., 2003; Kobielak et 
al., 2007). Bulge stem cell activation responds to cyclic BMP2 and BMP4 expression 
within the dermis (Plikus et al., 2008). Dermal BMP signals progressively diminish 
during the resting period of the hair follicle cycle promoting the switch from quiescent to 
activated bulge stem cells (Plikus et al., 2008). 
Adhesion & Migration of Skin Stem Cells  
The adhesion molecules of skin stem cells are very important in their regulation. 
Interactions with support cells and the extra-cellular matrix (ECM) via adhesion 
molecules establish and maintain niche architecture, generate and transmit regulatory 
signals and control the frequency and nature of stem cell division.  There are several 
ECM proteins and adhesion molecules up-regulated in skin stem cells (when compared to 
differentiated keratinocytes) including: TNC, COL6A1, COL18A1, FBLN1, SPARC, 
ITGβ1, ITGβ4, ITGβ6 and P-cadherin (Fuchs, 2008; Jones et al., 2007; Morris et al., 
2004; Rhee et al., 2006; Tumbar et al., 2004). The importance of these adhesion 
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molecules is highlighted by a study which deleted ITGβ1 and α-catenin from basal 
keratinocytes and resulted in random orientation of cell division and alterations in 
epidermal homeostasis (Lechler and Fuchs, 2005). These results support the hypothesis 
that signals generated from the proper interaction between adhesion molecules and the 
environment should either promote directional migration (out of niche for regeneration) 
or inhibit motility (keeping the stem cells within the niche). 
Under normal circumstance, bulge stem cells have very limited motility as it is 
crucial for the cells to remain in the niche (Roh et al., 2005). During normal tissue 
regeneration transit-amplifying (TA) cells migrate out of the niche so it is not surprising 
that these daughters of bulge stem cells exhibit a high motility (Roh et al., 2005). 
However, bulge stem cells can be induced to migrate downward to the hair follicle as 
well as outward to resurface the epidermis in response to wounding (Taylor et al., 2000). 
After injury or during normal turnover, keratinocytes become activated; simultaneously 
secreting and responding to growth factors and cytokines (Rizvi and Wong, 2005; Tomic-
Canic et al., 1998; Watt et al., 2006). After mechanical injury, bulge stem cells will start 
migrating and proliferating, generating TA cells (Blanpain and Fuchs, 2009; Owens and 
Watt, 2003). The cells undergo significant changes to their junction and adhesion 
molecules, a critical part of this process. Importantly, hemidesmosomes (HDs) are 
dissolved to allow for migration. These migrating keratinocytes produce a different set of 
membrane molecules, such as vitronectin and fibronectin receptors (importantly integrin 
α5β1), which replace the collagen receptor (integrin α2β1) and further permit migration 
(Cavani et al., 1993; Haapasalmi et al., 1996; Singer and Clark, 1999). The growth 
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factors active during wound healing such as epidermal growth factor (EGF), keratinocyte 
growth factor (KGF) and TGFβ are all potential regulators of these processes (Nanney et 
al., 1996; Werner et al., 1994; Zambruno et al., 1995). 
Stem Cells and Cancer Cells 
 Similarities between stem cells and cancer cells have long been recognized as 
both have the capacity for self renewal and unlimited replication. The identification of 
key pathways for stem cell regulation and cancer progression (such as Notch, Hedgehog 
and Wnt) reveals further parallels. Stem cells are increasingly becoming recognized as a 
model system for properties exhibited by cancer cells as well as potential targets of 
carcinogenic pathways. 
Self-renewal 
Self-renewal is the process in which a stem cell divides asymmetrically or 
symmetrically to generate one or two daughter stem cells that have a developmental 
potential similar to the mother cell.  As stem cells and cancer cells share the ability to 
self-renew, it is reasonable to propose that newly arising cancer cells appropriate (or 
“hijack”) the self-renewing cell division machinery normally expressed in stem cells. 
There is evidence showing that many pathways classically associated with cancer also 
regulate normal stem cell development. For example, the prevention of apoptosis by 
forced expression of the oncogene bcl-2 results in increased numbers of hematopoietic 
stem cells (HSCs) in-vivo, suggesting that cell death has a role in regulating the 
homeostasis of HSCs (Domen et al., 1998; Domen and Weissman, 2000). Additionally, 
the potent oncogene c-Myc controls the balance between stem cell self-renewal and 
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differentiation, presumably by regulating the interaction between hematopoietic stem 
cells and their niche (Satoh et al., 2004; Wilson et al., 2004). Other signaling pathways 
associated with oncogenesis have been shown to play a role in stem cell self renewal; 
such as the Notch (Dontu et al., 2004; Hitoshi et al., 2002; Shen et al., 2004; Vercauteren 
and Sutherland, 2004), SHH (Clement et al., 2007; Liu et al., 2006), and Wnt signaling 
pathways (Dravid et al., 2005; Reya et al., 2003).  
Importance of Environment 
 As previously discussed, the primary function of the niche is to maintain 
undifferentiated stem cells, although the precise mechanisms are still unclear. Stephen 
Paget’s “Seed and Soil” Hypothesis, introduced over a hundred years ago, postulates that 
the location of secondary tumors reflect the “fertile soil” that site/organ provides for the 
“seeds” of cancer cells (Paget, 1889). However, the role of stroma in the tumor 
microenvironment has only recently become recognized as a major influencing factor of 
cancer progression. Normal fibroblastic stroma preserves epithelial cell quiescence and 
effectively inhibits epithelial cell transformation (and consequent tumorigenesis) 
demonstrating a stromal dominance over neoplastic cells (Kenny and Bissell, 2003; 
Kuperwasser et al., 2004; Maffini et al., 2004). Correspondingly, activated stroma 
(typically damaged by age, genetic mutation, injury/inflammation, or cancer cell 
influence) can provide a more supportive microenvironment for expanded tumor growth 
(Barcellos-Hoff and Ravani, 2000; Kurose et al., 2002; Kurose et al., 2001; Li et al., 
2007; Olumi et al., 1999). 
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Normal epithelium interacts with the underlying stromal compartment through a 
basement membrane composed mainly of collagen IV and laminin. Upon carcinoma 
progression, the previously uncompromised basement membrane is degraded and 
malignant epithelial cells invade into the underlying reactive stroma (Mueller and 
Fusenig, 2004). Invasive carcinoma cells then directly interact with activated fibroblasts 
(referred to as tumor-associated fibroblasts (TAFs), carcinoma-associated fibroblasts 
(CAFs) or reactive stroma) which remain in a chronic state of activation and ultimately 
support tumor progression (Kunz-Schughart and Knuechel, 2002a; Kunz-Schughart and 
Knuechel, 2002b; Orimo et al., 2005). Stromal cells influence epithelial cell behavior by 
secreting various extra-cellular matrix proteins, chemokines, cytokines, growth factors, 
proteases, and protease inhibitors. Altogether the tumor micro-environment, similar to the 
stem cell niche, creates a specialized environment which is permissive for cancer 
progression.  
Integrins 
Integrins make up a large family of heterodimeric transmembrane cell-matrix 
receptors composed of an α and a β subunit. 18 α and 8 β subunits have been described 
and they can assemble to form 24 different heterodimers, each with a different specificity 
to extra-cellular matrix proteins such as fibronectin, laminin, vitronectin, collagen and 
thrombospondin (Figure 1-2). Each of the 24 integrins appears to have unique functions 
made evident by their ligand specificities and varying phenotypes of the knockout mice. 
Integrins form a functional link between the extra-cellular matrix and the 
intracellular signaling pathways which influence cell morphology, survival, motility,  
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proliferation, migration and invasion (Aplin et al., 1999). Binding of integrins to the 
extra-cellular matrix causes a conformation change allowing signals to be transmitted 
into the cell (in what is known as “outside-in signaling”) activating several downstream 
signaling events (Juliano et al., 2004). Since integrins do not have an intrinsic catalytic 
activity, any downstream signaling must be modulated by integrin-associated proteins. 
Some of the more important integrin-mediated signals rely on the recruitment of the Src 
and FAK families of protein tyrosine kinases (Arias-Salgado et al., 2003; Arias-Salgado 
et al., 2005). There are three main signaling pathways activated by integrins that are 
critical for both cancer cells and stem cells: cytoskeletal organization (adhesion/cell 
migration), cell proliferation and cell survival pathways.  
Adhesion/Cell Migration 
In cells, adhesion and actin polymerization are dependent on one another. 
Adhesions provide nucleation points which support actin polymerization, but actin 
polymerization determines rates of adhesion and possibly nucleates adhesions containing 
activated integrins (Butler et al., 2006). Following the binding of ECM proteins, α-actinin 
and talin are recruited to the β-integrin cytoplasmic tail rapidly followed by the actin-
binding protein vinculin, altogether forming a stable focal adhesion (Martin et al., 2002). 
Removal of any of the proteins comprising this linkage leads to the disruption of the 
entire adhesion structure (Vicente-Manzanares et al., 2009). These integrin-mediated 
adhesions serve as traction points for contractile or tensional forces through their 
interaction with the actin cytoskeleton.  
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Integrin clustering by ligand binding also results in the oligomerization of focal 
adhesion kinase (FAK). Both FAK and vinculin can interact with the Arp2/3 complex, 
which controls the assembly of a branched actin filament network in the lamellipodium 
(Butler et al., 2006). Additionally, autophosphorylation of FAK results in the recruitment 
of Src through the SH2 domain and ultimate activation of GTPases RhoA, Rac1 and 
Cdc42.  These GTPases, by way of a variety of effectors, lead to actin nucleation, 
cytoskeletal contractility, branched F-actin growth and thus membrane protrusion and 
migration (Huveneers and Danen, 2009; Kiyokawa et al., 1998; ten Klooster et al., 2006). 
Cell Survival  
Most adherent cell types depend on integrin mediated adhesion for survival 
(Giancotti and Ruoslahti, 1999). Loss of adhesion causes cells to undergo a form of 
programmed cell death referred to as anoikis (Frisch and Screaton, 2001). Anoikis likely 
prevents cells from growing in inappropriate sites after losing adhesion from their 
original surroundings, thus maintaining the integrity of tissues. Integrin-mediated cell 
adhesion in 2-dimensional culture systems stimulates Bcl-2 expression and PKB/AKT 
activity, which in turn mediates survival signals (Giancotti and Ruoslahti, 1999). In the 
absence of serum factors, integrin-mediated adhesion to fibronectin enhances survival by 
activating JNK in a FAK dependent manner (Almeida et al., 2000). Alternatively, ligand-
free integrins can trigger apoptosis of fully adherent cells via the recruitment and 
activation of caspase-8. This suggests that a given integrin expression profile renders a 
cell dependent on a specific ECM environment for its survival (Stupack et al., 2001; 
Varner et al., 1995). 
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Proliferation 
Through the activation of Rac and ERK, integrin-mediated cell adhesion in 
normal untransformed cells also regulates the G1 phase of the cell cycle (Assoian and 
Schwartz, 2001; Schwartz and Assoian, 2001). Activated Rac and ERK contribute to the 
induction of cyclin D1 in mid-G1 phase. Ultimately, these events lead to the 
phosphorylation of the retinoblastoma protein (pRb) and entry into S phase. RTK 
stimulation and integrin-mediated adhesion can each independently activate ERK 
explaining the transcriptional regulation of cyclin D1. However, it is the combination of 
RTK and integrin signaling (i.e. when adherent cells are stimulated) which creates strong 
and sustained ERK activity necessary for cell cycle progression (Chen et al., 1996; 
Renshaw et al., 1997). 
Integrin-mediated adhesion, through ERK signaling, also leads to the induction of 
p21cip1 in early G1 phase and suppression or re-localization of the cyclin dependent 
kinase inhibitors p21cip1 and p27kip1 in mid–late G1 phase, coincident with activation of 
cyclin-E–Cdk2. Additionally, increased expression of c-Myc through activation of c-Src 
in response to integrin-mediated adhesion drives entry into S-phase (Benaud and 
Dickson, 2001). The organization of the actin cytoskeleton by integrins is also essential 
for adhesion-regulated proliferation. Integrin mediated control of Rho GTPases activity 
(enzymes critically involved in actin cytoskeletal organization) is an important aspect of 
adhesion mediated regulation of cyclin D1 and cdk-inhibitors. 
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Activation 
Current information regarding the regulation of integrin signaling focuses on 
conformational changes, which affect the affinity of the integrin to its ligand. Many 
integrins are expressed and remain in a low-affinity binding state until cellular 
stimulation transforms them into a high-affinity form, an event known as integrin 
activation, which can modify cell adhesion (Qin et al., 2004). Because information travels 
from the inside to the outside of the cell, this is often referred to as ‘inside-out’ signaling 
(Hynes, 2002). Although the details are still unclear, inside-out signaling typically leads 
to the binding of talin to the β-integrin cytoplasmic tail, followed by a conformational 
change of the integrin and finally an increased affinity of the integrin to the ligand 
(Anthis et al., 2009; Ling et al., 2003; Ye et al.). Other signaling events modulating 
integrin signaling (either activating or deactivating) mainly either manipulate talin-
binding or cause valency changes of the integrin (which affects ligand affinity) (Carman 
and Springer, 2003; Hynes, 2002). This regulation of integrins is essential for their 
biological functions made most obvious in platelet aggregation. If the affinity of the 
major platelet integrin (αIIbβ3) is not tightly controlled, the effects on the clotting 
process would be disastrous, leading to either thrombosis or bleeding disorders (Banno 
and Ginsberg, 2008; Kim et al., 2009). 
Trafficking 
 It has been known for almost 20 years that integrins are continuously internalized 
and recycled back to the cell surface (Bretscher, 1989; Bretscher, 1992). The trafficking 
of integrins by the endosomal pathway can influence their functions, polarize 
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distributions and affect the signaling of other associated growth factor receptors. Integrin 
endocytosis and recycling has been described as a process which moves the adhesion 
receptors from the back to the front of a migrating cell (Bretscher, 1996); however, there 
is still no evidence for such long-ranging machinery.  
Depending on the heterodimer, integrin internalization occurs through both 
clathrin-dependent and -independent mechanisms. However, not all integrins have been 
characterized leaving much still unclear (known data summarized in (Caswell et al., 
2009)). It has been speculated that the same integrin can be internalized by different 
mechanisms in response to various environmental cues (Ramsay et al., 2007). It has also 
been suggested that the mechanism of internalization will affect the trafficking route and 
subsequently the state of the cell (Caswell and Norman, 2006). 
Following endocytosis, the fate of the internalized integrin is determined in the 
early endosome: degradation, short-loop recycling or long-loop recycling. Most of the 
evidence accumulated thus far links integrins to the long-loop recycling; passing 
internalized integrins (such as α5β1, α2β1, α6β1, αLβ2, αVβ3) from the early endosome 
to the perinuclear recycling compartment before returning to the plasma membrane via a 
Rab11-dependent mechanism (Caswell and Norman, 2006). This recycling path is 
dependent on other signaling molecules such as PKB/Akt, GSK3β and PKCε (Roberts et 
al., 2004). So far only αVβ3 has been shown to be recycled in the short-loop pathway via 
Rab4, a pathway dependent on the recruitment of PKD1 (Roberts et al., 2001; Woods et 
al., 2004). 
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Integrin β4 
The β4 integrin subunit (ITGβ4) was initially identified as a tumor-associated 
antigen (TS180) associated with metastasis (Falcioni et al., 1989; Falcioni et al., 1988).  
ITGβ4 was soon identified as a partner for the α6 integrin subunit, to which it exclusively 
binds (Hemler et al., 1989; Kennel et al., 1989). A majority of integrins link the ECM to 
the actin cytoskeleton (Geiger et al., 2009), however α6β4 integrin is a laminin receptor 
which mediates the hemidesmosome (HD) formation linking the ECM with the 
intermediate filament cytoskeleton (Borradori and Sonnenberg, 1996; Green and Jones, 
1996; Nievers et al., 1999). The α6β4 integrin is unique in other ways; most obvious is 
that while all other integrins consist of a very short cytoplasmic domain of ~50 amino 
acids, the cytoplasmic tail of α6β4 (specifically the tail of ITGβ4) is 20 times as long 
(Hogervorst et al., 1990; Suzuki and Naitoh, 1990; Tamura et al., 1990). The extended 
tail is characterized by two pairs of fibronectin type III repeats separated by a connecting 
sequence. This cytoplasmic domain is crucial for the formation of HDs as well as any 
downstream signaling of α6β4 integrin stimulation (Merdek et al., 2007; Murgia et al., 
1998; Nikolopoulos et al., 2004; Nikolopoulos et al., 2005). 
Role in hemidesmosomes 
 The importance of ITGβ4 is highlighted in the knockout mice which suffer from 
junctional epidermolysis bullosa (blistering of the skin) in response to mechanical stress 
and die shortly after birth (Dowling et al., 1996; Fuchs et al., 1997; Georges-Labouesse et 
al., 1996). The blistering is due to the loss of functional hemidesmosomes (HDs) leading 
to the detachment of the skin from the basement membrane. There are currently two 
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different types of HDs described in the literature; classic or type I HD which contain 
α6β4 integrin, BPAG 180 and 230, HD1/plectin and CD151 (Litjens et al., 2006; Nievers 
et al., 1999) and type II HDs which lack the BPAG proteins (Uematsu et al., 1994). The 
linkage of integrin α6β4 to the intermediate filament through HD1/plectin is critical for 
both types of HD formation (Niessen et al., 1997; Rezniczek et al., 1998; Sanchez-
Aparicio et al., 1997). 
 Although it is important for HDs to provide strength and stability to the cell, they 
must also be dynamic and disassemble for cell migration during wound closure or 
carcinoma invasion (Daisuke Tsuruta, 2003; Geuijen and Sonnenberg, 2002; Ito et al., 
2005; Levy et al., 2007). Although the process is still unclear, studies investigating the 
mechanism of HD disassembly have found that growth factor induced phosphorylation of 
several sites within the ITGβ4 cytoplasmic tail plays a crucial role in this process. EGF 
signaling triggers PKC dependent phosphorylation on S1356, S1360, S1364 and S1424, 
all of which can individually lead to at least partial HD disassembly (Germain et al., 
2009; Rabinovitz et al., 2004; Santoro et al., 2003; Wilhelmsen et al., 2007).  
Signaling/Role in Cancer 
Although integrin α6β4 is polarized to the basal region of normal epithelia, an 
early observation described its localization in several types of carcinoma cells as diffuse 
(Tennenbaum et al., 1993). This phenomenon supports the hypothesis that α6β4 switches 
from a mechanical adhesive device into a signaling competent receptor during the 
progression from normal epithelium to invasive carcinoma (Lipscomb and Mercurio, 
2005; Santoro et al., 2003). Integrin α6β4 plays a role in a wide variety of intracellular 
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signaling, but it contains no inherent kinase activity and the precise mechanisms are still 
unclear. There are currently two different but not mutually exclusive hypotheses: the β4 
intracellular domain functions as a signaling adaptor and/or the localization of α6β4 with 
tetraspanin-enriched membrane micro-domains enhances signaling abilities (Trusolino et 
al., 2001; Yang et al., 2004). The mechanisms of α6β4 signaling in cancer are made even 
more complex considering there is both ligand-dependent and -independent activation 
(O'Connor et al., 1998). 
Integrin α6β4 signaling initiates a number of signaling cascades such as MAPK, 
PI3K/Akt and Shc/Src. These signals modulate many cellular behaviors like adhesion, 
proliferation, survival, motility and gene expression. Following stimulation, the 
cytoplasmic tail of ITGβ4 can be phosphorylated on several different tyrosine and serine 
residues. Y1494 is located in the consensus SH2 binding motif which binds phosphatase 
SHP2 (and possible SHP1) and activates Src (Bertotti et al., 2006; Merdek et al., 2007; 
Shaw, 2001; Unkeless and Jin, 1997). Studies found that Y1494 phosphorylation is 
necessary for the integrin α6β4 activation of PI3K (Dutta and Shaw, 2008; Shaw, 2001). 
PI3K activation can then lead to Akt/PKB and Rac stimulation (Shaw et al., 1997). 
Y1526 is another crucial site for integrin α6β4 signaling. When phosphorylated, Y1526 
can recruit Shc, Grb2 and Sos thus activating Ras and stimulating the MAPK, Jnk and 
Erk signaling cascades (Mainiero et al., 1997). Studies have also shown that integrin 
α6β4 regulated Rac activity in mammary epithelial cells leads to NFκB activation 
(Weaver et al., 2002; Zahir et al., 2003).  
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Integrin α6β4 can also indirectly control the expression of various genes critical 
for cancer progression. Activation of the PI3K/Akt pathway leads to the phosphorylation 
of 4E-BP1 by mTor. 4E-BP1 phosphorylation releases the repression on translation factor 
eIF-4E leading to the up-regulation of VEGF as well as other target genes (Chung et al., 
2002). Additionally, integrin α6β4 can activate the transcription factors c-Jun and STAT3 
through ErbB2 (Guo et al., 2006), NFκB through EGFR (Weaver et al., 2002; Zahir et al., 
2003) and NFAT through PI3K (Jauliac et al., 2002). The introduction of ITGβ4 into 
MDA-MB-435 cells leads to a drastic change in the genetic profile including the up-
regulation of S100A4/Metastasin, HDAC4 and SFRP1 and the down-regulation of FOS, 
EGR1 and GADD45A (Chen et al., 2009).  
The culmination of these signaling events leads to the promotion of characteristics 
essential for cancer, such as survival, proliferation, motility, invasion and anchorage 
independent growth. PI3K promotes survival as well as motility and invasion in 
carcinoma cells and angiogenesis within a tumor (Baril et al., 2007; Lee et al., 2008; 
Nikolopoulos et al., 2004; O'Connor et al., 1998; Rabinovitz and Mercurio, 1996; Rossen 
et al., 1994; Shaw et al., 1997; Wei et al., 1998). An increase in NFκB signaling leads to 
survival in addition to anchorage independent growth (Weaver et al., 2002; Zahir et al., 
2003). The previously mentioned Shp2/Src signaling pathway aids in anchorage-
independent growth when activated through integrin α6β4 (Bertotti et al., 2006). 
Altogether, integrin α6β4 signaling facilitates the survival and growth of carcinoma cells, 
especially when in a stressful environment like hypoxia (Baril et al., 2007; Chen et al., 
2009; Lipscomb and Mercurio, 2005; Lipscomb et al., 2005). Studies found that cell 
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surface expression of integrin α6β4 is up-regulated in hypoxic environments, indicating 
how crucial this signaling is for cancer cell survival (Yoon et al., 2005). 
In addition to the signaling capabilities, integrin α6β4 can also support cell 
migration and invasion through mechanical means. Antibodies specific for integrin α6β4 
inhibit carcinoma cell migration on laminin-1 as well as the formation of filopodia and 
lamellipodia (Rabinovitz and Mercurio, 1997; Rabinovitz et al., 1999). Integrin α6β4 
interacts with the F-actin in filopodia, lamellipodia and the retraction fibers of invasive 
cells (O'Connor et al., 1998; Rabinovitz and Mercurio, 1997; Rabinovitz et al., 1999). 
Further studies demonstrated that traction forces on the base of the lamellae are exerted 
directly though integrin α6β4 in cells plated on either laminin or anti-α6β4 antibodies 
(Rabinovitz et al., 2001).  
In Breast Cancer 
 Although ITGβ4 expression is also linked to poor patient prognosis in a variety of 
cancers (Raymond et al., 2007), its role in breast cancer has been of particular interest. 
Similar to other integrins, integrin α6β4 associates and cooperates with a variety of 
growth factor receptors, such as EGFR (Mariotti et al., 2001), ErbB2 (Gambaletta et al., 
2000), and Met (Chung et al., 2004; Trusolino et al., 2001). Although all of these 
receptors have known roles in cancer, ErbB2 is a dominant oncogene in breast cancer and 
is amplified in 25-30% in human breast tumors (Muthuswamy, 2006). Further studies of 
human samples found that ITGβ4 expression is correlated to breast cancer size and 
nuclear grade (Diaz et al., 2005), and significantly correlates with basal-like breast cancer 
(Lu et al., 2008). More recently, EGFR was also found to be over-expressed in the basal-
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like subgroup of breast-cancer and α6β4 was identified as important for its distribution 
and function (Gilcrease et al., 2009).  
Overall, these data demonstrate that integrin α6β4 plays a critical role in cancer 
and any further insight into the regulation of this molecule may prove invaluable towards 
the development of a targeted therapy. 
In the Epidermis 
The role of ITGβ4 in skin is moderately well defined; however there are several 
seemingly conflicting reports. As previously mentioned, the skin of mice nullizygous for 
ITGβ4 fails to remain attached to the basement membrane causing the mice to die shortly 
after birth. In humans, this disease is called junctional epidermolysis bullosa (JEB) or 
epidermolysis bullosa lethalis because of the high mortality rate associated with the 
disorder. A majority of JEB cases involve either homozygous or compound heterozygous 
mutations in the laminin 5 chain (the ligand for α6β4), but some compound heterozygous 
mutations have also been detected in the ITGβ4 gene (Niessen et al., 1996; Vidal et al., 
1995). When samples from skin lacking ITGβ4 were examined histologically, integrin α6 
was barely detectable, suggesting that it is unstable in the absence of ITGβ4 (Dowling et 
al., 1996; van der Neut et al., 1996). Some studies find mice lacking ITGβ4 maintain 
normal skin morphogenesis and show no defects in keratinocyte proliferation, survival or 
differentiation (DiPersio et al., 2000; Raymond et al., 2005). However, others report 
degeneration of basal keratinocytes and defective epidermal growth and migration in 
cells expressing a signaling defective ITGβ4 (Dowling et al., 1996; Nikolopoulos et al., 
2005). Supporting the latter finding, the cytoplasmic domain of ITGβ4 can bind to the 
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adaptor protein Shc and thus activate Ras/MAPK contributing to keratinocytes 
proliferation (Mainiero et al., 1997). Follow-up studies found that ITGβ4 needs to 
physically interact with an EGF-R family member to amplify pro-proliferative signals 
(Guo et al., 2006). These seemingly conflicting findings regarding the role of ITGβ4 in 
proliferation may be the product of the method used to nullify the signal. Signaling 
defective ITGβ4 may compete for binding sites on proliferation-promoting proteins; 
whereas this would not be a concern in ITGβ4 null cells. This would explain why the 
signaling defective ITGβ4 cells show a decrease in proliferation (Dowling et al., 1996; 
Nikolopoulos et al., 2005), whereas the ITGβ4 null cells do not (DiPersio et al., 2000; 
Raymond et al., 2005). It is possible that integrin β1, the other binding partner of integrin 
α6, provides a functionally redundant signal in regards to proliferation. 
Arrestins 
Family Members 
There are four known and well studied genes encoding arrestins. The expression 
patterns of arrestin 1 (SAG/visual arrestin) and arrestin 4 (ARR3/cone arrestin) are 
restricted, primarily localized to the visual sensory tissue where they regulate rhodopsin 
photoreceptor signaling. However, arrestin 2 (ARRB1/β-arrestin-1) and arrestin 3 
(ARRB2/β-arrestin-2) are ubiquitously expressed and interact with the vast majority of 
other GPCRs. However, recent phylogenetic analysis has identified another 6 members of 
the arrestin family in humans: ARRDC1, ARRDC2, ARRDC3, ARRDC4, ARRDC5 and 
TXNIP (Alvarez, 2008). This same study also identified VPS26 as a close relative to the 
family. 
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Role in GPCR regulation 
Arrestins were first discovered to have a role in a conserved two-step mechanism 
for regulating G protein-coupled receptors (GPCRs) (Gurevich and Gurevich, 2006b). In 
response to a stimulus, GPCRs activate heterotrimeric G proteins, but in order to turn off 
this response, the activated receptors need to be silenced. Receptor silencing is initiated 
by phosphorylation by a class of serine/threonine kinases called G protein coupled 
receptor kinases (GRKs). GRK phosphorylation creates a high-affinity binding site for 
arrestins on the GPCR; for example, the affinity of the β2 receptor-arrestin 2 interaction 
increases 10-30 fold after phosphorylation by GRK2 (Lohse et al., 1992). GPCR 
phosphorylation recruits arrestins from the cytoplasm to the plasma membrane, a binding 
which blocks further G protein-mediated signaling and redirects signaling to alternative 
G protein-independent pathways (Figure 1-3).  
Arrestins block GPCR coupling to G proteins via two mechanisms: 
desensitization and sequestration. The arrestin binds to the cytoplasmic tip of the receptor 
and masks the binding site for the heterotrimeric G-protein (preventing activation); this is 
called desensitization. However, β-arrestins can further suppress signaling by linking the 
receptor to elements of the internalization machinery (clathrin and clathrin adaptor AP2). 
This promotes receptor internalization via clathrin coated pits and subsequent transport to 
an internal compartment, known as the endosome. Subsequently, the receptor could be 
either targeted for degradation (typically via the lysosome) or recycled back to the plasma  
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membrane where it can signal again (re-sensitization). The strength of arrestin-receptor 
interaction seems to play a role in this choice: tighter complexes tend to increase the 
probability of receptor degradation, whereas more transient complexes typically favor 
recycling (Gurevich and Gurevich, 2006b). Also important in the post-endocytotic sorting 
of the internalized proteins is the ubiquitination of the receptor and/or arrestin (Bhandari 
et al., 2007; Shenoy and Lefkowitz, 2003; Shenoy et al., 2001; Shenoy et al., 2008). 
Receptor and self ubiquitination can also be controlled by the arrestin and will be further 
discussed shortly.  
Beyond GPCR regulation 
In addition to GPCRs, arrestins can bind to several other signaling proteins and 
thus affect signaling (Gurevich and Gurevich, 2004). Arrestins can act as scaffolding or 
bridging proteins which brings together signaling partners and increases efficiency. There 
is a dramatic conformational change between free and receptor-bound arrestin and this 
can influence the affinity of these other signaling molecules. Receptor-bound arrestins 
serve as scaffolds for MAP kinase cascades, bringing together apoptosis signal-regulating 
kinase 1 (ASK1) and c-Jun N-terminal kinase 3 (JNK3), as well as the kinase c-Raf-1 and 
extracellular signal-regulated kinase 2 (ERK2), thereby facilitating signaling in the 
ASK1-Map kinase kinase 4 (MKK4)-JNK3 and c-Raf-1-MAP/ERK kinase 1 (MEK1)-
ERK2 pathways (Luttrell et al., 2001; McDonald et al., 2000). Additionally, arrestin3 
binds both PKB/Akt and its negative regulator protein phosphatase 2A (PP2A), 
permitting the deactivation of Akt (Beaulieu et al., 2005). Arrestin3 also facilitates the 
deactivation of JNK3 by recruiting the dual-specificity phosphatase MKP7 (Willoughby 
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and Collins, 2005). When ERK2 and JNK3 are activated by the arrestin-receptor complex 
they stay bound to the endosomes and thus cannot translocate to the nucleus, affecting 
transcription (Luttrell et al., 2001; McDonald et al., 2000).  
Arrestins can influence gene transcription in other ways. Both arrestin2 and 
arrestin3 interact directly with IκBα, an inhibitor of NF-κB, following stimulation of the 
β2-adrenergic receptors. This interaction prevents its phosphorylation and degradation 
and thereby repressing the activity of NF-κB (Gao et al., 2004; Witherow et al., 2004). 
These arrestins regulate NF-κB signaling in another way; by interacting with the tumor 
necrosis factor receptor-associated factor 6 (TRAF6), preventing its auto-ubiquitination 
and the subsequent activation of NF-κB (Wang et al., 2006). There is further evidence 
that arrestins can effect gene transcription more directly by entering the nucleus. 
Arrestins 2 and 3 can be present in both the cytoplasm and nucleus, depending on various 
post-translational modifications (Wang et al., 2003). After translocation into the nucleus, 
arrestins can associate with transcription factors such as p300 and CREB and modulate 
transcription (Kang et al., 2005; Ma and Pei, 2007). 
In addition to signaling molecules, arrestins also recruit ubiquitin ligases to the 
receptors: the E3 ubiquitin ligase Mdm2 is mobilized by mammalian β-arrestins and 
ubiquitinates GPCRs (Shenoy et al., 2001), and the E3 ligase Deltex mobilized by Kurtz 
(an arrestin specific to Drosophila) ubiquitinates the Notch receptor (Mukherjee et al., 
2005). Through proteins known as ARTs (arrestin related trafficking adaptors), arrestins 
can recruit other E3 ligases including CHIP, NEDD4 and ITCH/AIP4 (Bhandari et al., 
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2007; Shenoy et al., 2008; Zhang et al., 2009). This function allows the arrestin to have 
even more control over the fate of its target. 
Role in non-GPCR signaling 
Arrestins can bind membrane proteins not part of the GPCR super-family, some 
of which are important for development and cancer. These include both receptor and non-
receptor tyrosine kinases, non-classical 7TMRs (like Smoothened and Frizzled), ion 
channel receptors, and cytokine receptors. Similar to their interactions with GPCRs, 
arrestins can act as a scaffolding protein (creating new signaling complexes), control 
internalization/cellular localization or promote degradation with the non-GPCR targets. 
In response to IGF stimulation, β-arrestin acts as an E3 ligase adaptor. After IGF 
binds to the tetrameric IGF1R, β-arrestin recruits Mdm2 to the receptor. Mdm2 
ubiquitinates IGF1R, thus leading to its internalization. Once internalized, β-arrestin is 
part of a new “signalsome” and mediates the activation of ERK, which then translocates 
to the nucleus and activates transcription. IGF1R is ultimately degraded by the 
proteosome (Lin et al., 1998).  
β-arrestin 2 binds to the type III TGFβ receptor, a co-receptor that contributes to 
TGFβ signaling through currently unknown mechanisms (Chen et al., 2003). 
Downstream of TGFβ-binding, β-arrestin is essential for the activation of Cdc42, which 
is then responsible for actin reorganization leading to chemotaxis and filipodial extension 
(Mythreye and Blobe, 2009). β-arrestin can also internalize the bound TGF-β receptor, 
attenuating TGFβ-mediated SMAD signaling (Chen et al., 2003). 
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In the Hedgehog (Hh) pathway, arrestins play a role in receptor signaling as well 
as sub-cellular localization. Upon Hh binding, Patched (Ptc) repression is relieved and 
Smoothened (Smo) is phosphorylated by GRK-2. This initiates the formation of a 
complex with β-arrestins and the molecular motor Kif3A. The Smo-β-arrestin-Kif3A 
complex translocates Smo to the primary cilium where Smo cleaves Gli into its active 
form. Active Gli then translocates down the primary cilium and into the nucleus where it 
activates transcription of downstream targets (Kovacs et al., 2008; Molla-Herman et al., 
2008). Smo activation and phosphorylation by GRK2 can also recruit β-arrestin 2 to the 
cell membrane which promotes clathrin mediated endocytosis (Chen et al., 2004). 
Relevant to epidermal stem cell regulation, β-arrestins have been implicated as 
important mediators of both canonical and non-canonical Wnt signaling, but in different 
capacities. β-arrestin 1 interacts with phosphorylated Dishevelled 1/2 (Dsh1 & Dsh2) 
(Chen et al., 2001), and was shown to synergistically enhance LEF-mediated 
transcription when co-expressed with either Dsh proteins. In canonical Wnt signaling, β-
arrestins also bind to Frizzled (Fz, receptor for Wnts) through Dsh and sequester the 
Axin/GSK3 destruction complex away from β-catenin, thus promoting its stabilization 
(Bryja et al., 2007). During non-canonical Wnt signaling, β-arrestins will complex with 
Dsh and AP-2 subsequently activating RhoA and Rac1 (Barnes et al., 2005). 
ARRDC3 
Arrestin domain containing protein 3 (ARRDC3, KIAA1376, TLIMP, ADC3) 
contains structural homology to β-arrestins which play an essential role in G protein-
coupled receptors (GPCRs) signaling and internalization (Alvarez, 2008; Seachrist and 
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Ferguson, 2003). Although ARRDC3 is classified as an α-arrestin, there is a cluster of 
acidic and hydrophobic residues in the C-terminus that may bind to clathrin, suggesting a 
possible role in membrane protein internalization (Alvarez, 2008).  
Prior to the work discussed in this thesis, there had been only one paper which 
looked at the function of ARRDC3 directly (Oka et al., 2006). The work of Oka et al. 
found that ARRDC3 is localized to the cell membrane, endosomes and lysosomes. This 
study also found that over-expression of ARRDC3 decreased cell proliferation and 
inhibited anchorage independent growth. Due to homology with thioredoxin binding 
protein 2 (TBP2 or vitamin D3 up-regulated protein-1), they investigated whether vitamin 
D3 affects ARRDC3 levels. Oka et al found the expression of ARRDC3 is induced in 
cells treated with vitamin D3 and, to a lesser extent, PMA. Interestingly, ARRDC3 
expression was up-regulated when cells were treated with PPARγ agonists troglitazone 
and pioglitazone, but not PPARα agonist clofibrate. However, increases in ARRDC3 
expression lead to decreases in PPARγ signaling. These data suggest that ARRDC3 is 
part of a negative-feedback regulatory pathway of PPARγ.  
Although only directly investigated in the work previously mentioned, there have 
been a few passing references to ARRDC3, mostly in genetic screens. ARRDC3 was 
recently found within a cluster on chromosome 5 deleted in 17% of basal-like breast 
cancers (compared to 0% in luminal breast-cancers) suggesting a role as a tumor 
suppressor (Adelaide et al., 2007). When comparing pre-eclamptic placentas to normal, 
ARRDC3 expression was significantly higher in the pre-eclamptic samples. ARRDC3 
expression was also high in the STOX1 (Storkhead Box 1, a transcription factor in the 
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Forkhead-family) over-expression model of preeclampsia and 4 Forkhead binding sites 
were identified and verified (Rigourd et al., 2008). This data suggests that ARRDC3 may 
be regulated in response to stress by the members of the forkhead family of transcription 
factors, proteins with know roles in development as well as cancer. 
 Although limited, the current data suggests that ARRDC3, similar to other 
arrestin family members, regulates signaling pathways and subsequently effects cellular 
behaviors such as proliferation, anchorage independent growth and survival. 
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Abstract: 
Control of stem cell migration is essential for organogenesis, tissue homeostasis 
and response to injury, but the molecular mechanisms governing this process within the 
stem cell niche are still unclear. In this study, we show that ARRDC3 (KIAA1376, 
TLIMP) is more highly expressed within human adult skin stem cells when compared to 
daughter transit-amplifying cells.  We demonstrate that ARRDC3 is a novel post-
translational regulator of ITGβ4 (ITGβ4). During dynamic regulation of ITGβ4 in 
migrating cells, ARRDC3 interacts with the cytoplasmic domain of serine 
phosphorylated ITGβ4 on the lagging edge and targets it for internalization and 
proteosome dependent degradation. Over-expression of ARRDC3 inhibits stem cell 
motility while down-regulation induces active migration, but does not diminish multi-
potency. Our results identify a novel mechanism of integrin regulation that controls the 
transition from anchored stem cells to migrating daughter cells. 
Introduction: 
Adult epithelial stem cells are generally found within distinct locations tightly 
adherent to the basement membrane (Raymond et al., 2009).  Within skin, multipotent 
stem cells are located in the hair follicle bulge region, while daughter transit-amplifying 
(TA) cells are present in the hair bulb (Cotsarelis et al., 1990; Lyle et al., 1998; Morris et 
al., 2004). Several studies have identified genes over-expressed in the stem cell 
compartment of skin that help define stem cells and their niche (Morris et al., 2004; 
Ohyama et al., 2006; Tumbar et al., 2004). The challenge has now become trying to 
understand the functions of differentially expressed genes in maintaining stem cell 
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properties such as cell migration. During normal tissue homeostasis and tissue 
regeneration of wound healing, stem cells remain as permanent residents of the stem cell 
niche, while their progeny TA cells migrate away from the niche to repopulate the tissue 
(Adams and Watt, 1991; Ito et al., 2005; Roh et al., 2005). While a great deal is known 
about the molecular mechanisms of cell migration, these pathways have not been fully 
analyzed in the context of epithelial stem cells and it is also clear that additional key 
regulatory molecules have yet to be characterized. 
Members of the arrestin family of proteins represent components of the 
transmembrane receptor-binding complex that have been shown to regulate a number of 
cellular processes including cell migration (reviewed in (Kendall and Luttrell, 2009)). 
Recently, new members of the arrestin family have been identified, called “Arrestin 
Domain Containing Proteins” (ARRDC1-5, also ADC1-5) that have unidentified targets 
and functions (Aubry et al., 2009). ARRDC3 contains structural homology to the well-
characterized β-arrestins that play an essential role in G protein-coupled receptor (GPCR) 
signaling and internalization (Alvarez, 2008; Seachrist and Ferguson, 2003). Other 
arrestin family members form complexes that co-localize with key vesicular trafficking 
proteins as well as endosomes (McDonald et al., 1999). Although ARRDC3 is classified 
as an α-arrestin, there is a cluster of acidic and hydrophobic residues in the C-terminus 
that may bind to clathrin, suggesting a role in membrane protein internalization (Alvarez, 
2008). Although prior work has suggested a role for ARRDC3 in PPARγ signaling and 
endosomal functions (Oka et al., 2006), no link to surface molecules has been 
demonstrated. 
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Integrins are a class of cell surface receptors that are known to play an important 
role in epithelial cell adhesion and migration (Rabinovitz and Mercurio, 1997; Streuli, 
2009; Vicente-Manzanares et al., 2009), but there is still much to learn about the 
regulatory networks that control integrin function. Several integrins are expressed in skin 
stem cells, including the α6β4 heterodimer (here out referred as ITGβ4) (Watt, 2002).  
ITGβ4 is the core component of hemidesmosomes that anchor cytoplasmic keratin 
filaments to the extracellular basement membrane (Rezniczek et al., 1998; Schaapveld et 
al., 1998). Humans with ITGβ4 mutations suffer from a disease known as junctional 
epidermolysis bullosa (blistering of the skin) which demonstrates its significant role in 
tissue homeostasis (Gil et al., 1994; Niessen et al., 1996; Vidal et al., 1995). ITGβ4 null 
mice also demonstrate junctional epidermolysis bullosa in response to mechanical stress 
and die shortly after birth (Dowling et al., 1996; Fuchs et al., 1997; Georges-Labouesse et 
al., 1996). However, the role of ITGβ4 in the skin stem cells beyond adhesion to the 
basement membrane is currently unclear. 
In addition to adhesion, ITGβ4 confers the ability of cells to migrate and resist 
apoptotic stimuli, (Lipscomb and Mercurio, 2005; Lipscomb et al., 2005; Rabinovitz and 
Mercurio, 1996; Wilhelmsen et al., 2006). Migration of stem cell progeny is critical for 
normal tissue homeostasis and wound healing as demonstrated by the re-epithelialization 
process after the wounding of skin (Ito and Cotsarelis, 2008; Ito et al., 2005; Levy et al., 
2007). During keratinocyte migration, hemidesmosomes, containing ITGβ4, are 
disassembled by a mechanism that has not been well-characterized (Borradori and 
Sonnenberg, 1999; Litjens et al., 2006; Margadant et al., 2008). During wound healing, as 
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well as in carcinoma invasion, growth factors such as EGF are elevated and lead to 
hemidesmosome disassembly (Mainiero et al., 1996; Rabinovitz et al., 1999). EGF 
stimulation induces phosphorylation of ITGβ4 on a variety of serine and tyrosine residues 
(Germain et al., 2009; Mainiero et al., 1996; Rabinovitz et al., 2004) resulting in 
hemidesmosome disassembly and mobilization of ITGβ4 to actin-rich protrusions 
(Germain et al., 2009; Rabinovitz et al., 1999; Rabinovitz et al., 2004; Wilhelmsen et al., 
2007). More recently, phosphorylation of ITGβ4-S1424 was found enriched on the 
trailing edge of migrating cells and implicated in the dissociation of ITGβ4 from 
hemidesmosomes (Germain et al., 2009). This dynamic regulation of ITGβ4 is such a 
process that could potentially mediate the transition from anchored stem cells to actively 
migrating TA cells in human skin.  
In this study we demonstrate that a new arrestin family member, ARRDC3, is up-
regulated in skin stem cells. Using in vitro assays of stem cell behavior, we show that 
ARRDC3 has significant effects on cell migration. Our molecular studies establish that 
ARRDC3 affects stem cell function through a novel regulatory pathway involving the 
internalization and degradation of ITGβ4.  
Results: 
ARRDC3 is expressed in skin stem cells. 
We previously demonstrated key functional differences (such as cell migration 
and self-renewal) between keratinocyte stem cells and TA cells of the human hair follicle 
(Roh et al., 2005). We next wished to determine differences in the genetic expression 
profiles of these two cell types in an effort to elucidate the mechanism for the functional 
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changes. An enriched stem cell population was obtained by micro-dissection of telogen 
hair follicle bulges, while TA cell enriched population was dissected from anagen hair 
follicle bulbs (Figure 2-1A). RNA isolated from these cell populations was then used for 
subtraction hybridization. Stem cell-enriched cDNAs were then cloned and sequenced, 
identifying ARRDC3 as a differentially expressed gene.  
Real-time PCR analysis shows that ARRDC3 expression is 3.41 fold higher in 
telogen bulge cells when compared to anagen bulb cells (Figure 2-1B). Interestingly, the 
anagen bulge has a 2.03 fold higher level of ARRDC3 expression when compared to 
anagen bulb (Figure 2-1B); suggesting high ARRDC3 levels are maintained throughout 
the hair cycle and are increased during stem cell activation of telogen follicles. 
Immunofluorescence and immunohistochemistry of adult human skin sections and hair 
follicles confirmed that ARRDC3 protein is increased in keratinocyte stem cells of the 
bulge when compared to cells in the lower follicle (Figures 2-1C&D). As shown in tissue 
sections, cells in the basal layer of the bulge region demonstrate the most intense staining 
with some apparent expression in suprabasal cells as well.  Altogether these data 
demonstrate that ARRDC3 is highly expressed in epithelial stem cells and down-
regulated in daughter/TA cells. 
Interestingly, when co-stained for the skin stem cell marker keratin 15 (K15) 
(Lyle et al., 1998), only a subset of ARRDC3 positive cells are positive. This data, along 
with the staining from the skin sections, suggests that although ARRDC3 is more highly 
expressed in the stem cell region of the skin, it is not a stem cell marker. In addition, only 
a subset of keratin 15 positive cells also expressed ARRDC3 (Figure 2-2). 
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ARRDC3 sequence and structure analysis 
ARRDC3 has a high degree of sequence homology throughout several species, 
suggesting a similarly important role. ClustalW alignment on the amino acid sequence of 
ARRDC3 from G. gallus, E. caballus, R. norvegicus, M. musculus, P. troglodytes, P. 
abelii, H. sapiens, and B. taurus show at least a 98.3% similarity to the human sequence 
(Figures 2-3A & 2-4). Primary sequence analysis of ARRDC3 using secondary structure 
prediction algorithm PSPIRED found secondary structure elements consistent with other 
arrestin family members (Figure 2-3B). 3D-Jigsaw (Bates et al., 2001) generated a 
putative tertiary structure of ARRDC3 (Figure 2-5). Using GenThreader, we found that 
ARRDC3 is predicted to be a close structural homologue to VPS26 (vacuolar protein 
sorting) with an identical probability value of 5e-11 (Jones, 1999; McGuffin and Jones, 
2003; Shi et al., 2006). VPS26 is a key part of the retromer, a complex of proteins 
involved in endocytotic trafficking, endosomal sorting and the transcytosis of polarized 
cells (Alvarez, 2008; Bonifacino and Hurley, 2008; Bonifacino and Rojas, 2006; Haft et 
al., 2000; Seaman, 2005). Comparing the known structure of VPS26 and the projected 
structure of ARRDC3 reveals marked similarities (Figure 2-5).  Mutations made in the 
domains of VPS26 homologous to ARRDC3 cause an abrogation of its functions (Reddy 
and Seaman, 2001), suggesting ARRDC3 also plays a role in endocytosis or vesicular 
trafficking. 
Expression Pattern of ARRDC3 in Human Tissues 
ARRDC3 mRNA levels were analyzed in a variety of normal human tissues using 
northern blot analysis (Figure 2-6A). We found that ARRDC3 expression levels vary in 
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different tissue types. ARRDC3 expression is exceptionally high in the placenta, but is 
also high in skeletal muscle, kidney, liver and lung. ARRDC3 is weakly expressed in 
brain, skeletal muscle, colon, thymus, and small intestine. Moderate expression is seen in 
the heart and peripheral blood leukocytes (Figure 2-6A). Although widely expressed in 
human tissues, the expression patterns within specific cell types of a tissue are yet to be 
determined. Specifically, it is unclear whether ARRDC3 expression is restricted to cells 
within the adult stem cell niche. 
We next analyzed the cellular localization of ARRDC3 using a monoclonal 
antibody generated in our lab for immunofluorescence. Confocal microscopy images of 
hair follicle stem cells show endogenous ARRDC3 is weakly distributed throughout the 
cytoplasm, but is concentrated at certain sections of the cell membrane. The presence of 
ARRDC3 foci near the cell membrane suggests an association with intracellular vesicles 
(Figure 2-6B). This observation further validates the notion that ARRDC3 regulates a 
cell-surface protein. 
ARRDC3 co-localizes with endosomal markers 
Confocal microscopy images of hair follicle stem cells show that endogenous 
ARRDC3 concentrates at certain sections of the cell membrane. The presence of 
ARRDC3 foci near the cell membrane suggests an association with intracellular vesicles 
(Figures 2-6B & 2-7A). To confirm this, we examined the co-localization of ARRDC3 
with endosomal markers using a proximity ligation assay (PLA). ARRDC3 strongly co-
localizes with EEA1 and Clathrin, while only minimal signal is seen with CAV1 (Figure 
2-7B&C). To further visualize positioning within the cell, images obtained from confocal 
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microscopy were used to generate a 3D reconstruction of the cells. This reconstruction 
demonstrated that ARRDC3 co-localizes with endosomal proteins evenly throughout the 
cell. Overall, these data indicate ARRDC3 primarily associates with endosomes which 
are internalized in a clathrin dependent manner.  
ARRDC3 interacts with ITGβ4 
Due to the homology with other arrestin proteins (Figure 2-4B) (Luttrell and 
Lefkowitz, 2002), we hypothesized that ARRDC3 has similar biological functions. To 
determine potential molecular targets, a yeast-two hybrid library screen using full length 
ARRDC3 as bait was performed. This screen identified a fragment of the cytoplasmic tail 
of ITGβ4 (Figure 2-8A). This interaction can be seen endogenously in telogen cells by 
immuno co-precipitating ITGβ4 with an anti-ARRDC3 antibody (Figure 2-8B). 
Phosphatase inhibitors are necessary to see this interaction, suggesting that ITGβ4 
requires phosphorylation for binding to occur. Since ITGβ4 has several critical serine and 
tyrosine phosphorylation sites within the cytoplasmic tail, we tested for the enrichment of 
phospho-ITGβ4 after using an anti-ARRDC3 antibody for immuno co-precipitation 
(Figure 2-8B&C). Quantification using densitometry revealed that anti-ARRDC3 
antibody precipitated approximately 53% of the phospho-ITGβ4 compared to the amount 
precipitated with ITGβ4. 
Immunofluorescence of skin stem cells demonstrated co-localization of ARRDC3 
and ITGβ4 within the cell (Figure 2-8C). Interestingly, there were areas of the cell that 
appeared to show a deliberate segregation of the proteins, specifically near cell-cell 
boundaries. These data suggest that the interaction between ARRDC3 and ITGβ4 is 
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dynamic and dependent on the relative position within the cell and/or phosphorylation 
status. To further investigate the intercellular positioning of the ARRDC3/ITGβ4 
complex, we generated a 3D construction of a PLA from confocal images. Cultured stem 
cells showed a polarized localization of ARRDC3/ITGβ4 on the basal layer of the cell 
(Figure 2-8D), suggesting that ARRDC3 interacts with ITGβ4 while in HDs. Giving 
further support to this theory, PLA analysis of ARRDC3 with HD marker PLEC1 found 
the same pattern of co-localization in the basal layer of the cell (Figure 2-8E).  
ARRDC3 regulates ITGβ4 protein levels 
 Since β-arrestins target GPCRs for internalization/degradation (Luttrell and 
Lefkowitz, 2002), we hypothesized that ARRCD3 has a similar effect on ITGβ4. Using 
two different siRNAs to down-regulate ARRDC3 in cultured skin stem cells, we found an 
inverse relationship between ARRDC3 expression and ITGβ4 protein levels (Figure 2-
9A). To further verify the effects of altered ARRDC3 on ITGβ4, we infected skin stem 
cells with an adenovirus co-expressing ARRDC3 and GFP and then looked at ITGβ4 
levels using immunofluorescence. ITGβ4 was lost from ARRDC3-GFP over-expressing 
cells while there was no change in either neighboring uninfected cells or control-GFP 
infected cells (Figure 2-9B). Using flow cytometry on non-permeabilized cells, we found 
cell surface levels of ITGβ4 were completely lost in cells over-expressing ARRDC3, 
although a residual amount appeared to be retained within the cytoplasm when examined 
by immunofluorescence (Figure 2-9C).  
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ITGβ4 regulation by ARRDC3 is proteosome dependent 
As ITGβ4 affects numerous signaling pathways, it was unclear whether the 
decreased protein level was an immediate response to the interaction with ARRDC3 or 
caused by a feedback pathway leading to a decrease in mRNA and subsequently protein 
level. To test this, we transfected the skin stem cells with either a control siRNA or an 
ARRDC3 targeting siRNA. RT-PCR analysis showed no changes in ITGβ4 mRNA 
levels, demonstrating the regulation of ITGβ4 by ARRDC3 is post-transcriptional (Figure 
2-10A). To exclude the possibility that protein synthesis was necessary for the increase in 
ITGβ4 after ARRDC3 repression, we treated cells with cyclohexamide and transfected 
with either control or ARRDC3 targeting siRNAs. Cells analyzed using 
immunofluorescence and western blot analysis revealed the treatment of cyclohexamide 
did not prevent an increase in ITGβ4 (Figures 2-10B). This further supports the notion 
that ARRDC3 regulates ITGβ4 protein directly and not through its synthesis.  
We next wanted to determine the mechanisms of ITGβ4 protein degradation and 
found that ARRDC3-mediated ITGβ4 protein degradation is inhibited in the presence of 
proteosome inhibitor lactacystin. This is demonstrated by both immunofluorescence and 
western blot analysis (Figure 2-11A&B).  ITGβ4 expression was not affected by the GFP 
control virus, either with or without proteosome inhibitor. When cells are examined using 
flow cytometry, the addition of the proteosome inhibitor does not prevent ITGβ4 removal 
from the cell surface (Figure 2-11C), supporting the notion that interaction with 
ARRDC3 causes the initial internalization of ITGβ4, a process that would be unaffected 
by downstream proteosome inhibition. The addition of lysosomal inhibitor chloroquin did 
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not affect the ARRDC3-induced decrease in ITGβ4 levels (Figure 2-12), suggesting that 
the degradation is solely dependent on the proteosome. 
ARRDC3 controls stem cell motility 
Stem cells are anchored within the niche whereas their progeny must be able to 
leave the niche and replenish tissues. Knowing ITGβ4 is involved in cell motility, we 
suspected that ARRDC3 affects the motility of skin stem cells. Stem cells from human 
skin (Roh et al., 2008) were infected with either a control siRNA, an siRNA targeting 
ARRDC3, or an adenovirus expressing ARRDC3 and then used to conduct a scratch 
assays. The wound widths were measured in Adobe Photoshop (arbitrary units) from 
images taken using a 4X objective. After 48 hours, cells with decreased ARRDC3 had 
almost a complete wound closure (0.91 to 0.24) whereas the control cells did not (0.95-
0.66). Additionally, the wound width for skin stem cells over-expressing ARRDC3 was 
only minimally decreased (0.95-0.82) (Figure 2-13A).  Motility in transit-amplifying 
cells isolated from the hair bulb was assayed in the same manner (Figure 2-13B). TA 
cells with low ARRDC3 demonstrated a faster wound closure rate (0.99-0.05) compared 
to control TA cells (0.97-0.17). TA cells engineered to over-express ARRDC3 that 
showed a significantly slower rate of migration (0.94-0.50) (p<0.0006). 
Our data so far suggests that ARRDC3 plays a role in controlling skin stem cell 
migration by regulating ITGβ4. To understand how ARRDC3 behaves in migrating stem 
cells, in-vitro scratch assays were used to identify actively migrating cells and the 
endogenous expression pattern of ITGβ4 and ARRDC3 was examined. Interestingly, 
ARRDC3 and ITGβ4 maintained co-localization only on the lagging edge of the 
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migrating cells (Figure 2-14A). Furthermore, when the leading edge of the cell was 
examined, the basal plane of the cell attached to the substratum showed high levels of 
ITGβ4 while ARRDC3 was present in the apical (top) plane. This suggests ARRDC3 
interacts with ITGβ4 in HDs about to be dissolved, but not in newly formed ITGβ4 focal 
adhesions. 
ARRDC3 interacts with ITGβ4 when phosphorylated at serine-1424 
 A novel phosphorylation site on ITGβ4 was recently identified as important in 
HD disassembly and shown to be enriched on the trailing edge of a migrating cell 
(Germain et al., 2009). As this phenotype mirrored our observations of ARRDC3, this 
residue was a good candidate for the phosphorylation site which facilitates interaction 
between ITGβ4 and ARRDC3.  The relative distributions of endogenous ARRDC3, 
ITGβ4 and ITGβ4-pS1424 in migrating skin stem cells were examined using confocal 
microscopy.  Supporting our hypothesis, we found almost a complete overlap of 
ARRDC3 and ITGβ4-pS1424 localization in migrating cells (Figure 2-14B). 
We then determined that ARRDC3 physically interacts with ITGβ4-pS1424 by 
endogenous immuno co-precipitation of skin stem cell lysates (Figure 2-8B).  
Densitometric analysis demonstrates that ~68% of ITGβ4-pS1424 is immuno co-
precipitated with an ARRDC3 antibody when compared to an ITGβ4 antibody. The 
densitometric ratio of precipitated pS1424/ITGβ4 is 6.6 fold higher in the ARRDC3 
immuno co-precipitation when compared to the ITGβ4 immuno co-precipitation.  
Collectively, these data suggest that following phosphorylation of ITGβ4-S1424, 
ARRDC3 binds to the cytoplasmic tail and promotes internalization of ITGβ4. This 
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occurs during HD disassembly either while the cell is migrating (a process localized on 
the lagging edge of cells) or during normal HD turnover (a perpetual event in resting 
cells) (Daisuke Tsuruta, 2003; Geuijen and Sonnenberg, 2002). 
ARRDC3 does not affect multi-potency 
To test whether ARRDC3 affected the multi-potency of stem cells, we generated 
stable human skin stem cell lines with altered ARRDC3 expression. The lines generated 
were analyzed for ARRDC3 and ITGβ4 levels using western blot analysis (Figure 2-
15A). We then induced the altered skin stem cells lines down epidermal, hair or 
sebaceous lineages. After induction, cells were examined for morphology and expression 
of differentiation markers.  
After sebocyte differentiation was induced, each cell line showed a marked 
increase in oil red O staining (not shown) and an increase in KRT7 expression when 
compared to the un-induced control (Figure 2-15B), indicating that ARRDC3 expression 
levels do not affect the ability of stem cells to undergo sebocyte differentiation. 
Epidermal markers are increased in all stem cell lines after epidermal differentiation 
indicating that ARRDC3 expression does not affect epidermal differentiation (Figure 2-
15C). Each skin stem cell line showed an up-regulation of K6HF after hair induction 
compared to the control, confirming that ARRDC3 expression does not affect the ability 
of stem cells to undergo hair differentiation (Figure 2-15D). 
ARRDC3 expression preserves an undifferentiated state in skin stem cells  
It was interesting to note that expression of ARRDC3 appeared to shift 
undifferentiated cells towards the sebaceous lineage. A low level of spontaneous 
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differentiation occurs in the cultured Telogen E6/E7 cells seen by the faint presence of 
keratin markers when the cells are undifferentiated. However, expression of keratin 1, 
involucrin and keratin k6hf are decreased in the skin stem cells over-expressing 
ARRDC3 and expression of keratin 7 is slightly increased. This suggests that ARRDC3 
may influence the spontaneous differentiation of telogen cells down the sebaceous 
lineage (Figure 2-15). 
To test how differentiation affected ARRDC3 protein levels, we analyzed lysates 
from the parental skin stem cell line after differentiation along with the respective 
controls. Western blot analysis shows ARRDC3 levels decrease with sebocyte and hair 
differentiation but increase with skin differentiation. These changes did not correlate to 
the changes in ITGβ4 expression suggesting that it is unlikely that ARRDC3 is the only 
factor regulating ITGβ4 during skin stem cell differentiation (Figure 2-16). 
Loss of ARRDC3 causes abnormal whisker follicles and loss of fur in mice 
 In an effort to determine the role of ARRDC3 in vivo, we generated a knock-out 
mouse model using mouse embryonic stem cells, on a 129 background, generated by 
Sanger Institute (cell line CG0361, created using gene-trap technology). C57Bl6/129 
chimeras were created with these cells and mated to C57Bl6 mice to test for germline 
transmission, with the presence of the gene-trap verified by PCR amplification of the 
NEO-cassette. 
 Unfortunately, all of our efforts to create a genotyping protocol which 
distinguishes between the homozygous and heterozygous null mice have been 
unsuccessful. SIGTR performed 5’ RACE on ES cell RNA and determined the gene-trap 
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is located between exons 1 and 2 (in intron 2) of the ARRDC3 locus. We initially tried to 
use forward and reverse PCR primers (positioned every ~200 bp in the 3.5kb intron) in 
the intron paired with a reverse primer on the 5’ end of the genetrap or a forward primer 
on the 3’ end of the genetrap (respectively) to amplify the insertion site. Unfortunately, 
there was no amplification.  We next tried to generate a Southern genotyping protocol. 
However, all attempts to PCR amplify this region of the wild-type strand (in order to 
create a probe) have failed.  Consultations with the trouble-shooting departments of 
Genewiz and Genetyper indicate that this locus is “mostly inaccessible” likely due to 
supercoiling and/or CpG methylation. Both companies indicated that these difficulties 
could eventually be overcome with the right PCR conditions. For the mice discussed in 
this thesis, heterozygotes and homozygous null mice were distinguished by phenotype.  
 ARRDC3 heterozygous mice are viable, develop normally and are fertile. 
However, as the mice age, they seem to progressively lose their fur (Figure 2-17A). 
Additionally, ARRDC3 null mice are born without whiskers and lose their fur much 
faster when compared to the heterozygotes (Figure 2-17B). It was interesting to note that 
although all mice start to lose their fur, the rate and pattern of the loss appears to be 
different for each mouse. Some had large patchy losses whereas some presented with an 
overall thinning of the fur. However, as mice were not housed separately it is possible 
this phenotype is actually due to mice barbering one another. Histological examination of 
the whisker pads from ARRDC3 null mice show morphological abnormalities in the 
whisker follicles (Figure 2-18A). Additionally, the dermis is much thinner in the null 
mice and there are fewer hair follicles present compared to wild-type littermates (Figure 
 52
2-18B). It is possible the loss of ARRDC3 led to increased migration of hair follicle stem 
cells out of the niche. This would lead to stem cell pool exhaustion and the loss of hair 
follicle homeostasis (i.e. decreased hair follicles). As hair follicles provide structure to 
the skin, which helps to maintain the thickness of the dermis, their loss is likely the cause 
of the thin epidermal layer. However, all of these observations are preliminary as the 
mice are still on a mixed background and only a few mice have been examined.   
Discussion: 
In the present study, we demonstrate that ARRDC3 is highly expressed in the 
stem cell compartment of human skin. As it does not affect differentiation, the main 
function of ARRDC3 appears to be suppressing motility. This is especially critical at the 
time of stem cell activation when the stem cells divide asymmetrically to self-renew and 
produce a committed daughter TA cell. Since the stem cell must remain behind while the 
TA cells migrate away, high levels of ARRDC3 are likely needed within the stem cells to 
prevent migration. Indeed, we saw the highest levels of ARRDC3 in the hair follicle stem 
cell compartment in the telogen phase when stem cells are in the early stages of being 
activated. We saw elevated, but comparatively lower levels of ARRDC3 in stem cells of 
anagen stage follicles when the stem cells are quiescent and stable.  
Although the role of ITGβ4 in cell migration has been studied extensively, there 
is yet to be a clear understanding of how HD regulation is involved in this process.  In 
cultured keratinocytes, there is a constant turnover of HDs (Daisuke Tsuruta, 2003; 
Geuijen and Sonnenberg, 2002). It is thought that this dynamic state helps to maintain 
cells competent for migration, when HDs need to be rapidly disassembled to allow for 
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detachment from the basement membrane. This hypothesis explains why skin stem cells 
maintain high expression of both ARRDC3 and ITGβ4.  
Our data introduces a new hypothesis for HD disassembly during cell migration. 
In this mechanism, ARRDC3 interacts with ITGβ4 phosphorylated on S1424 by PKCα 
after the cell has received migration stimuli (Germain et al., 2009). Upon this interaction, 
ITGβ4 located on the lagging edge of the cell becomes endocytosed, dissolving the HD, 
and sent to the proteosome for degradation. This disruption of adhesion molecules at the 
lagging edge allows the cell to migrate. Although our data clearly demonstrates that 
ARRDC3 promotes the internalization of ITGβ4, it is unclear whether it is directly 
involved in the trafficking to the proteosome. Although over-expression of ARRDC3 
leads to degradation of ITGβ4, it is possible that there is a point after internalization 
where other signals from the cell could contribute to its fate; either degradation or 
trafficking. It is unclear whether ARRDC3 also plays a role in re-localizing ITGβ4 to the 
leading edge of the cell where it helps form and stabilize motility structures (filopodia 
and lamellae) (Lipscomb and Mercurio, 2005; Mercurio et al., 2001b; Rabinovitz et al., 
2004; Santoro et al., 2003).  When treated with a proteosome inhibitor, cells over-
expressing ARRDC3 have slightly higher ITGβ4 surface protein levels compared to 
untreated cells; suggesting at least a small fraction of internalized protein is returned to 
the cell surface when it cannot be degraded. Additionally, the basal ITGβ4 and apical 
ARRDC3 staining patterns seen on the leading edge of the cells suggests a role beyond 
degradation. It would be interesting to test whether an ITGβ4-binding deficient mutant of 
ARRDC3 still affects ITGβ4 protein levels and cell motility. 
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While the ARRDC3-induced changes in ITGβ4 protein levels are modest, the 
affects on cell motility are pronounced suggesting the balance between stationary and 
motile states in skin stem cells is delicate. Motility has significant implications for stem 
cell biology because stem cells need to stay within the growth and differentiation 
restricted environment of the niche. We did not see an effect of ARRDC3 expression on 
in-vitro differentiation, but it is possible that aberrant differentiation or tissue homeostasis 
would be seen in-vivo due to mis-localization of the cells. This study also does not imply 
that ITGβ4 signaling or ARRDC3 expression does not influence the differentiation of 
adult keratinocyte stem cells, only that altered ARRDC3 levels do not prevent induced 
differentiation in-vitro. Indeed, skin stem cells expressing ARRDC3 tended to have a 
lower level of spontaneous differentiation as measured by marker expression in the un-
induced cells (Figure 2-15B-D). As VPS26 is involved in receptor transcytosis in 
polarized cells, it is also possible that ARRDC3 plays a role in polarizing the skin stem 
cells during asymmetric cell division (Eaton, 2008). 
Our findings may also have a significant implication in wound healing. Upon 
injury, keratinocytes secrete a number of cytokines and growth factors (Jones et al., 1998; 
Litjens et al., 2006; Margadant et al., 2008; Wilhelmsen et al., 2007). Depending on the 
type of injury keratinocytes will differentiate, proliferate or migrate. During tissue repair, 
HDs must be deconstructed to permit migration and thus regulation of ARRDC3 would 
likely be required for the ability to heal wounds. These data are also relevant to cancer 
biology as many aspects of wound healing (cell migration, loss of cell polarity, de-
differentiation, and proliferation) are also characteristics of aggressive cancer cells. 
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Additionally, ITGβ4 increases the migration and invasion properties in cancer cells, thus 
any mechanism involved in its regulation could be used and/or altered in cancer cells.  
The necessity of phosphatase inhibitors to observe the interaction between 
ARRDC3 and ITGβ4 suggests that phosphorylation of ITGβ4 is either necessary for or 
stabilizes the interaction. The enrichment of phosphorylated forms of ITGβ4 in co-
immunoprecipitation experiments further supports this. The identical cellular distribution 
of ARRDC3 and ITGβ4-pS1424 in both migrating cells and resting cells (Figure 2-14B 
and data not shown) identifies ITGβ4-pS1424 as a candidate phosphorylation site 
required for ARRDC3 interaction.  This phosphorylation enhances the interaction 
between ARRDC3 and ITGβ4 although it is still unclear whether this occurs before or 
after the disassembly of the HD. ITGβ4-S1424 is important to HD dynamics (Germain et 
al., 2009) and it is possible that this phosphorylation allows ARRDC3 to interact with and 
then causes the internalization of ITGβ4. As S1424 is not within the interacting fragment 
of ITGβ4 identified in the yeast-two hybrid screen, the phosphorylation needs to either 
cause a conformation change or recruit other proteins thus allowing the interaction to 
occur. Our data does not exclude other possible important phosphorylation events during 
ITGβ4 internalization; S1356, S1360 and S1364 are also significant during HD 
disassembly (Germain et al., 2009; Rabinovitz et al., 2004; Wilhelmsen et al., 2007). It is 
also possible that ARRDC3 only interacts with ITGβ4 after HD disruption and the 
increased ARRDC3/ITGβ4-pS1424 is a spurious correlation, not a causative one. Indeed 
data discussed in Chapter 3 showing the ARRDC3/ITGβ4 interaction in cells lacking 
HDs supports this. 
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Altogether, our data suggests that ARRDC3 plays a role in ITGβ4 trafficking, a 
process critical in the regulation of skin stem cell migration. Although not required for 
development, the importance of ARRDC3 is highlighted by the loss of fur and whiskers 
in knock-out mice. Based on our data, it is likely that the skin stem cells in ARRDC3-null 
mice exhibit an increase in motility, causing them to migrate out of the niche escaping its 
growth and differentiation inhibitive environment. This would ultimately lead to 
exhaustion of the stem cell pool and defective homeostasis, explaining why the 
phenotype becomes more pronounced as the mouse ages.  
An interesting question raised by our data is whether ARRDC3-mediated 
internalization is the result of a specific chemotactic stimulation or if it is an inherent 
feature of the skin stem cell which is up-regulated during migration. The latter is 
supported by the co-localization seen in resting cells (Figure 2-8C) and the fact that 
keratinocytes in culture maintain a constant HD turn-over even in the absence of 
migration. 
The discovery of a new protein that plays a role in migration and potentially 
trafficking generates many questions. Little is understood about integrin internalization or 
trafficking and less is known about the events at the lagging edge of migrating cells. Our 
findings open doors to further both lines of research.  
Methods: 
Dissection of Anagen Bulb and Telogen Bulge: Keratinocytes were isolated and cultured 
as described previously (Roh et al., 2004). Briefly, fresh adult human scalp skin from 
plastic surgical procedures was obtained from the Cooperative Human Tissue Network 
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(funded by National Cancer Institute) with Institutional Review Board approval, 
according to the Declaration of Helsinki Principles. One portion of the skin (1 2 cm) was 
treated with 4 mg per mL Dispase (Sigma-Aldrich, St Louis, Missouri) in Dulbecco's 
modified Eagle's medium (Invitrogen–Gibco, Carlsbad, California) overnight at 4°C. 
Using forceps, hair follicles were plucked from the Dispase-treated skin, and segregated 
into telogen club hairs based on their morphology under a dissecting microscope. Plucked 
anagen follicles were dissected to remove the upper outer root sheath corresponding to 
the bulge region. A second portion of the skin was dissected without Dispase treatment to 
obtain the matrix area at the bottom of the hair bulb. The telogen and anagen bulb hair 
fragments were either used as explant cultures directly or were digested with 0.05% 
trypsin–ethylene diamine tetra-acetic acid (EDTA) (Gibco) for 10 min, and then Versene 
(Gibco) was added (1.33:1) for an additional 10 min. Cells were centrifuged and plated 
onto tissue culture plastic dishes (Falcon, St Louis, Missouri). The isolated cells and 
tissue fragments were then cultured in keratinocyte medium (KCM) (Roh et al., 2004) on 
a feeder layer of J2-3T3 fibroblasts that had been pre-treated with mitomycin C (15 g 
per mL) for 2 h. Media were changed every other day. For subsequent experiments, the 
trypsinization method was used to culture keratinocytes from the hair follicles. For gene-
expression analysis, the anagen bulb and telogen bulge were isolated using a dissecting 
microscope. The tissue was rapidly frozen on dry ice and stored at -80 C. Total RNA 
from telogen bulge and anagen bulb was extracted using the guanidine isothiocyanate 
method. 
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Subtraction Hybridization: The Clontech PCR-Select Differential Screening Kit was 
purchased from Clontech (cat# 637403). Manufacturer’s recommended protocol was 
followed. 
Co-immunoprecipitation: Cells were solubilized at 4 °C for 10 min in NP-40 lysis buffer 
(Boston Bioproducts) containing 1 mM sodium orthovanadate, 1 mM NaF, and protease 
inhibitors (Complete mini tab; Roche Applied Science). Aliquots of cell extracts 
containing equivalent amounts of protein were incubated overnight at 4°C with antibodies 
and protein-A/G-Sepharose (Santa Cruz) with constant agitation. Immune complexes 
were resolved by SDS-PAGE and transferred to nitro-cellulose. 
Northern Blotting Analysis: Pre-quantified RNA from BD Biosciences were subjected to 
agarose gel electrophoresis and transferred on to a nylon membrane. A fragment of DIG-
labeled ARRDC3 RNA was used for hybridization. Membrane was washed and DIG was 
detected immunologically and exposed on film. 
siRNA Sequence and Transfection: Three different siRNA oligos were designed targeting 
the following sequences in ARRDC3: 1- AAACACGGCCTTCTATGCCA, 2- 
AAAGGCGGAACAATCTTGCAC, and 3- AATCTTGCACCAGTGAGTGCT. siRNA 
duplexes against these target sequences were ordered from Qiagen along with three 
control target sequences. siRNA duplexes were transfected into cells using TransIT-TKO 
transfection reagent (Mirus) following the manufacturer’s recommended protocol. For 
experiments shown in this paper, duplexes 1 and 3 were pooled for maximum knockdown 
of ARRDC3.  
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Cloning and Generation of Stable Lines: pSuper vectors (Oligoengine) containing control 
shRNA (shCtl target sequence: TTCTCCGAACGTGTCACGT) and shRNAs targeting 
ARRDC3 (shARRDC3 target sequence A:GGCCTTGGCTACTACCAGT; shARRDC3 
target sequence C: GCGTGGAATATTCACTAAT) were generated in our lab per 
manufacturers recommended protocol. Full length human ARRDC3 cDNA and Flag-
LacZ fusion cDNA were cloned into the pBABE-puro expression vector (Addgene). 
Cells were transfected with TransIT Keratinocyte Reagent (Mirus) following 
manufacturers recommended protocol. Stable transformants were selected using 
puromycin and pooled. 
Adenoviral Preparation: Full length human ARRDC3 cDNA was initially cloned into 
pLEGFP (Clontech). The fragment containing ARRDC3+GFP (or GFP alone) was then 
cloned into Adeno-X LP CMV (Clontech) using the Adeno-X Expression System 2 kit 
(Clontech). Adeno-X maxi purification kit (Clontech) was used to isolate/purify the 
adenovirus. For all steps, the manufacturers recommended protocol was followed. The 
amount of virus needed was determined empirically.  
Proximity Ligation Assay: The PLA system from Olink was purchased (Mouse MINUS, 
Rat MINUS and Rabbit PLUS probe sets as well as the 613 detection kit). Telogen cells 
were cultured on poly-D lysine coated coverslips and fixed with acetone. PLA was 
performed following the manufacture’s recommended protocol.  
Yeast-2 Hybrid: The BD Matchmaker Yeast-2-Hybrid System (BD Biosciences) was 
used as per manufacturers recommended protocol, using full length ARRDC3 as bait and 
cultured telogen stem cell RNA. 
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Adenovirus Production: A GFP-tagged ARRDC3 adenoviral construct was generated 
using the AdenoX expression system from Clontech. Adenovirus was prepared using the 
AdenoX Maxi purification kit as per manufacturers recommended protocol. 
Western Blotting Analysis: Cell extracts were prepared from cultured cells lysed in NP-40 
lysis buffer (Boston Bioproducts) for 15 minutes and then clarified by centrifugation. 
Extracts containing equivalent amounts of total protein were resolved by SDS-PAGE and 
transferred to nitrocellulose membranes. Membranes were blocked for an hour using a 50 
mM Tris buffer (pH 7.5) containing 0.15 mM NaCl and 0.05% Tween 20 and 5% (w/v) 
Blocker (BioRad). Membranes were incubated overnight at 4°C in the same buffer 
containing primary antibodies (rabbit polyclonal targeting ARRDC3 (Abcam ab64817) or 
rabbit polyclonal targeting ITGβ4 (505, a generous gift from Arthur Mercurio, UMMS 
Worcester, MA or phospho-specific antibody pS1424 a generous gift from Isaac 
Rabinovitz, BIDMC & HMS Boston, MA). Proteins were detected by enhanced 
chemiluminescence (Pierce). For phospho-immunoblots, the blocking buffer for the 
primary antibodies contained 5% (w/v) BSA. 
Immunofluorescence Staining: Cells were cultured on coverslips and fixed with acetone. 
Cells were permeabilized by incubating with PBS+Triton and blocked with 5% goat 
serum. Coverslips were incubated with primary antibody (mouse monoclonal ARRDC3 
generated by our lab, rat monoclonal ITGβ4 439-9b (BD-Pharmingen cat# 555719) and 
rabbit polyclonal ITGβ4-pS1424 (generous gift from Isaac Rabinovitz, BIDMC & HMS 
Boston, MA) for 2 hr at room temperature or overnight at 4°C. After being washed, cells 
were then stained with secondary antibodies conjugated with either FITC or Texas-Red 
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(Vector) for 2 hours at room temperature. After washing, cover-slips were mounted on 
slides using vectashield (Vector) and slides were analyzed using a fluorescence 
microscope. 
Wound Assay: 8x105 Telogen or TA cells were plated in a 6-well plate in Keratinocytes 
SFM (Gibco). 24 hours after plating, cells were either transfected with siRNAs using 
TransIT-TKO (Mirus) or infected with adenovirus. 48 hours post transfection/infection; 
the cells were treated with 15µg/ml mitomycin C for two hours at 37°C. The monolayer 
was scratched with a P200 pipette tip and washed 3 times to remove floating cells. The 
wound closure was then monitored by digital photography. 
Cell Culture and In-vitro differentiation: Hair Differentiation- Cells were plated at a 
density of 5,000 cells/cm2. Cells were allowed to attach overnight in KCM without EGF 
and then changed to fresh EGF-containing KCM along with 3T3-J2 inserts. After 
overnight incubation, half of the 3T3-J2 inserts were replaced with DP inserts and all 
cells were fed with fresh media. Transwell inserts (Corning) for 12-well plates were 
prepared with 20,000 mytomycin C-treated 3T3-J2 cells per insert in KCM or 20,000 DP 
cells per insert in Chang medium C (Irvine scientific) supplemented with 10% FBS and 
P/S. Epidermal Differentiation- Cells are plated at a density of 20–25,000 cells/cm2 and 
allowed to attach overnight, and then changed to low-calcium medium, KGM 
(keratinocyte growth medium, Cellntec, Bern, Switzerland). After overnight incubation, 
keratinocytes were fed with fresh KGM supplemented with additional 1.5 mM CaCl2 and 
incubated for the indicated times (1-4 days). Sebaceous Differentiation-Cells were 
plated at a density of 20–25,000 cells/cm2 and allowed to attach overnight in sebocyte 
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media (DMEM and Ham F-12 (1:1, Gibco), 6% FBS (Gibco), 2% human serum (sigma), 
P/S, and EGF (10 nM, Sigma)] as describe previously (Akimoto et al., 2005). Cells were 
induced for sebocyte differentiation with sebocyte differentiation media containing 10 
µM Arachidonic acid (Sigma) in sebocyte media for 2-4 days. Cultured sebocytes were 
washed with propylene glycol twice for 5 minutes each, stained with 0.7% (w/v) Oil Red 
O (Sigma) in propylene glycol for 7 minutes with agitation, washed once with 85% 
propylene glycol in distilled water, and then rinsed in distilled water. Oil Red O staining 
was viewed with a light microscope. 
Generation of ARRDC3 -/- mice: ES cells on a 129 background with a gene trap inserted 
between exons 1 and 2 of ARRDC3 were purchased from SIGTR (cell line CG0361). 
Cells heterozygous for the targeted mutation were microinjected into C57BL/6 
blastocysts to produce chimeric offspring. Chimeras were mated to wild-type C57BL/6 
and tested for germline transmission using PCR amplification of the NEO cassette found 
in the genetrap. Heterozygotes were interbred to obtain homozygous mice. Homozygous 
mice were identified phenotypically.  
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ABSTRACT  
 
Large-scale genetic analyses of human tumor samples have been used to identify 
novel oncogenes, tumor suppressors and prognostic factors, but the functions and 
molecular interactions of many individual genes have not been determined. In this study 
we examine the cellular effects and molecular mechanism of the arrestin family member, 
ARRDC3, a gene preferentially lost in a subset of breast cancers. Oncomine data reveals 
that expression of ARRDC3 decreases with tumor grade, metastases and recurrences. 
ARRDC3 over-expression represses cancer cell proliferation, migration, invasion, growth 
in soft agar and in vivo tumorigenicity while down-regulation of ARRCD3 has the 
opposite effects. Mechanistic studies demonstrate that ARRDC3 acts in a novel 
regulatory pathway that controls the cell surface adhesion molecule, beta-4 integrin 
(ITGβ4), a protein associated with aggressive tumor behavior. Our data indicates 
ARRDC3 directly binds to a phosphorylated form of ITGβ4 leading to its internalization, 
ubiquitination and ultimate degradation. The results identify the ARRCD3-ITGβ4 
pathway as a new therapeutic target in breast cancer and demonstrate the importance of 
connecting genetic arrays with mechanistic studies in the search for new treatments. 
Key Words: ARRDC3/Breast Cancer/Integrin β4/TLIMP 
INTRODUCTION  
The basal-like subset of breast cancer was first identified as tumors lacking 
estrogen and progesterone receptors and HER2 amplification (“triple negative”) with a 
gene expression profile similar to basal/myoepithelial cells of the breast (Perou et al., 
2000). Basal-like breast cancers account for 8-37% of all breast cancers (depending on 
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the definition criteria) and are associated with a poor prognosis; increased development 
of distant metastasis, decreased survival rate and increased mortality (reviewed in (Rakha 
and Ellis, 2009; Rakha et al., 2008; Voduc and Nielsen, 2008)). Since these tumors lack 
expression of estrogen and progesterone receptors as well as HER2, there are limited 
treatment options and these are largely ineffective in treating patients suffering from 
basal-like breast cancer. 
Large-scale genetic analyses of human tumor samples have generated a wealth of 
molecular information and have identified potential tumor suppressors, oncogenes and 
prognostic factors (Perou et al., 2000; SÃ¸rlie et al., 2001; Sotiriou and Pusztai, 2009). 
The challenge now is to study the function of these new genes and understand their 
mechanisms of action in order to validate their clinical utility and confirm their potential 
use as targets for intervention. The arrestin family member ARRDC3 is one such gene 
that was recently found within a cluster on chromosome 5 deleted in 17% of basal-like 
breast cancers (compared to 0% in luminal breast-cancers) suggesting a role as a tumor 
suppressor (Adelaide et al., 2007). ARRDC3 contains structural homology to the arrestin 
family of proteins, which play an important role in the internalization and subsequent 
regulation of G protein-coupled receptors (GPCRs). Although ARRDC3 has been 
classified as an α-arrestin, there is a cluster of acidic and hydrophobic residues in the C-
terminus that may bind to clathrin, suggesting a role in membrane protein internalization 
(Alvarez, 2008). A role for ARRDC3 as a negative regulator of PPARγ signaling and 
endosomal functions has been suggested (Oka et al., 2006). 
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Integrins are cell surface adhesion molecules that mediate cell-extracellular 
matrix and cell-cell interactions. Binding of integrins to their ligands initiates a number of 
signaling events that modulate cellular behaviors such as adhesion, proliferation, 
survival, motility, gene expression and differentiation (Arnaout et al., 2005; Dowling et 
al., 1996; Fuchs et al., 1997; Germain et al., 2009; Hynes, 2002; Lipscomb and Mercurio, 
2005; Lipscomb et al., 2005; Mercurio et al., 2001a; Vicente-Manzanares et al., 2009; 
Watt, 2002; Wilhelmsen et al., 2006).  The ITGβ4 subunit was initially identified in 
cancer as a tumor-related antigen associated with metastasis (Falcioni et al., 1989; 
Falcioni et al., 1988) and was later found to promote motility and invasion in carcinoma 
cells (O'Connor et al., 1998; Rabinovitz and Mercurio, 1996; Rossen et al., 1994; Shaw et 
al., 1997; Wei et al., 1998). ITGβ4 signaling increases invasive potential and sustains the 
survival of carcinoma cells in stressful environments (Baril et al., 2007; Chen et al., 2009; 
Lipscomb and Mercurio, 2005; Yoon et al., 2005). Recent studies in human samples 
found ITGβ4 expression is correlated to breast cancer size and nuclear grade (Diaz et al., 
2005), and significantly associates with basal-like breast cancer (Lu et al., 2008). ITGβ4 
expression is also linked to poor patient prognosis in a variety of other cancers (Raymond 
et al., 2007). Despite its significance in tumor progression, surprisingly little is known 
about the regulation of ITGβ4 at the protein level. It is phosphorylated during signal 
transduction and is expected to be internalized, trafficked throughout the cell, and either 
recycled or degraded (Caswell and Norman, 2008; Caswell and Norman, 2006; Dutta and 
Shaw, 2008; Germain et al., 2009; Hemler, 2001; Rabinovitz et al., 2004; Wilhelmsen et 
al., 2007; Yoon et al., 2005). It has been hypothesized that after hemidesmosome 
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disruption, the newly liberated ITGβ4 is rendered capable for signaling. Activation 
results in the release of ITGβ4 from interactions with the keratin cytoskeleton and allows 
for de novo interaction with the actin cytoskeleton and signaling molecules (Lipscomb 
and Mercurio, 2005; Mitra and Schlaepfer, 2006; Rabinovitz and Mercurio, 1996; 
Wilhelmsen et al., 2007; Yoon et al., 2005). However, little is known about the 
mechanism by which this occurs.  
In order to understand the function of ARRDC3, we used over-expression and 
shRNA-mediated down-regulation studies in human breast cancer cells. We demonstrate 
significant effects on breast cancer cell migration and growth that coincided with 
dramatic effects on the cell surface protein ITGβ4. We also show that ARRDC3 
expression is inversely correlated to breast tumor grade. In this study we demonstrate that 
ARRDC3 acts as a novel regulator of tumor progression in breast cancer due to its effects 
on ITGβ4 internalization and degradation.  
RESULTS 
ARRDC3 expression is down-regulated during tumor progression 
To investigate how ARRDC3 expression is altered during carcinogenesis, we 
used Oncomine to analyze published microarray data. Levels of ARRDC3 mRNA are 
lower in breast cancer tissues compared to normal mammary gland tissue (Figure 3-1A). 
As normal mammary tissue is mostly fat whereas tumors contain varying levels of 
stroma, this alone is not conclusive. However, levels of ARRDC3 mRNA decrease upon 
the transformation of purified and cultured human mammary epithelial cells (Figure 3-
1B).  Oncomine data also reveal that there is a decrease in ARRDC3 mRNA in metastatic 
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tumors when compared to the primary tumor (Figure 3-1C). Additionally, ARRDC3 
expression is lower in breast cancer patients that relapsed within 5 years of initial 
diagnosis compared to tumors from patients that remained disease free for >5 years 
(Figure 3-1D). Combined, these data indicate that ARRDC3 repression occurs early in 
oncogenesis, decreases throughout tumor progression and indicates a poor prognosis. 
ARRDC3 affects in-vitro human cancer cell tumorigenicity 
 To evaluate the potential role of ARRDC3 as a suppressor of tumor growth, we 
generated stable cancer cell lines either over-expressing or repressing ARRDC3 in the 
basal-like breast cancer cell line MDA-MB-231. We first noticed a change in the 
comparative growth rates. When quantitated, ARRDC3 over-expression causes a 
decrease in cell growth rates whereas the repression of ARRDC3 increases cell growth 
(Figure 3-2A).  
To investigate the affect of ARRDC3 on invasiveness, the sub-lines were used in 
a Matrigel chemoinvasion assay. Over-expression of ARRDC3 in MDA-MB-231 cells 
caused a 50% reduction in the number of invasive cells where the repression of ARRDC3 
caused a two fold increase (Figure 3-2B).  
The sub-lines were then used in a scratch assay to test whether ARRDC3 affects 
cancer cell migration. We found a dramatic decrease in cell migration in the ARRDC3 
over-expressing sub-lines (Figure 3-2C). The sub-lines with repressed ARRDC3 
exhibited a significant increase in migration rate.  
We next evaluated the role of ARRDC3 in anchorage independent growth using 
the sub-lines.  After 4-weeks growth in soft agar, colony number and size were calculated 
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using ImageJ. There was a significant decrease in colony number in the ARRDC3 over-
expressing sub-lines. The sub-lines with repressed ARRDC3 demonstrated a significant 
increase in colony number (Figure 3-2D). ARRDC3 expression also affected the size of 
the colonies; sub-lines with repressed ARRDC3 had a higher percentage of colonies 
>200μm whereas lines over-expressing ARRDC3 had a lower percentage of colonies 
>200μm (Figure 3-2E). 
To evaluate the effect of ARRDC3 on viability, MTT assays were used to analyze 
MDA-MB-231 cells with either repressed ARRDC3 or over-expression of ARRDC3. 
Cells with altered ARRDC3 expression demonstrated no changes in cell viability when 
MTT signal was normalized to the total number of cells. However, when cells were 
assayed day 4 after mitomycin C treatment, cells with repressed ARRDC3 had increased 
viability while cells over-expressing ARRDC3 demonstrated decreased viability when 
compared to day 0 untreated cells (Figure 3-2F). 
ARRDC3 suppresses in-vivo tumorigenicity  
 To assess the role of ARRDC3 in tumor development in-vivo, 1x106 cells of the 
stable sub-clones of MDA-MB-231 cells were injected into the mammary fat pad of nude 
mice. All sub-clones formed tumors efficiently by 7-weeks in 85-100% of the mice 
suggesting that ARRDC3 does not affect in-vivo tumor incidence. However, the sub-lines 
with repressed ARRDC3 formed measurable tumors more quickly (2 weeks) when 
compared to the control line (3 weeks). In contrast, the formation of tumors from the 
ARRDC3 over-expressing line was delayed (4 weeks) when compared to the control line 
(3 weeks). Seven weeks post injection, all mice were euthanized and the tumors were 
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dissected and measured. ARRDC3 significantly suppressed tumor growth in-vivo as 
determined by the weekly and final tumor volume measurements (Figure 3-3A-C).  
To determine whether there was a difference in the proliferation of the tumor 
cells, sections from the xenograft tumors (n=5 tumors for each cell line) were stained for 
Ki67. As expected from the in-vitro studies, repressing ARRDC3 increases the percent of 
Ki67 positive cells by almost 2-fold, while over-expressing ARRDC3 decreases the 
number of Ki67 positive cells by approximately 3-fold (Figure 3-3D). When quantitated, 
these differences were statistically significant.  
When examined microscopically, all tumors displayed an undifferentiated solid 
tumor morphology (Figure 3-4). To assess the contribution of ARRDC3 to in-vivo tumor 
cell survival, H&E stained sections of the xenograph tumors were quantitatively 
evaluated for central necrosis using ImageJ software. Although larger tumors are 
generally more necrotic, tumors derived from the shARRDC3 lines contained 
significantly less necrosis when compared to control tumors (Figure 3-5B). In contrast, 
tumors from the ARRDC3 over-expressing cell line, although smaller, were highly 
necrotic (Figure 3-5B). When quantitated, these differences were statistically significant. 
When TUNEL staining was performed on sections from the xenograft tumors, the 
expression of ARRDC3 appeared to have no effect on the number of apoptotic cells 
(Figure 3-5C), suggesting that ARRDC3 acts independently from the apoptotic pathway. 
Altogether, these data demonstrate that ARRDC3 suppresses in-vivo tumor cell growth 
and possibly affects the viability of tumor cells. 
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ARRDC3 negatively regulates ITGβ4 
 Our early adeno-viral mediated over-expression experiments caused detachment 
of MDA-MB-231 cells from the substratum after one week in culture suggesting a defect 
in cell adhesion. The MDA-MB-231 human cancer cell depends on the cell surface 
adhesion molecule ITGβ4 for cell adhesion to laminin, survival, migration and invasion 
(Lee et al., 2008; Mercurio and Rabinovitz, 2001; Shaw et al., 1997). To determine 
whether ARRDC3 expression directly influences ITGβ4 levels in breast cancer cells, 
transient over-expression and RNAi analyses were performed using the MDA-MB-231 
cell line. Over-expression of ARRDC3 causes a significant decrease in ITGβ4 protein 
levels by Western blot. Conversely, cells transfected with a siRNA targeting ARRDC3 
demonstrate a marked increase in ITGβ4 (Figure 3-6A). To verify that ITGβ4 was only 
affected in cells with altered ARRDC3, MDA-MD-231 cells were infected with an 
ARRDC3 and GFP co-expressing adenovirus and evaluated for ITGβ4 levels using 
immunofluorescence. Only GFP+ cells demonstrated a decrease in ITGβ4 surface 
expression while there was no change in ITGβ4 protein levels in control GFP-only 
infected cells (Figure 3-6B). Therefore, it is unlikely that the decrease in ITGβ4 levels is 
in response to a paracrine signaling pathway as ARRDC3 over-expression does not affect 
neighboring cells.  Flow cytometric analysis showed that over-expression of ARRDC3 
induces a complete lack of ITGβ4 protein at the cell surface (Figure 3-6C). 
ARRDC3 regulates ITGβ4 protein levels in a proteosome-dependent manner 
To help determine whether ARRDC3 regulates ITGβ4 at the level of mRNA 
expression or post-translationally, MDA-MB-231 cells were treated with cyclohexamide 
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after infection with either an adenoviral ARRDC3 & GFP virus (adARRDC3) or a 
control GFP-only virus (adGFP). Down-regulation of ITGβ4 in adARRDC3 infected 
cells was detected by western blot analysis and immunofluorescence despite treatment 
with cyclohexamide (Figure 3-7). These data demonstrate that ARRDC3 regulation of 
ITGβ4 protein levels is a post-translational process leading to increased degradation that 
does not require transcription of new genes. 
 We next wanted to determine the mechanism of ITGβ4 degradation in breast 
cancer cells. MDA-MB-231 cells were treated with the proteosome inhibitor lactacystin 
prior to infection with adARRDC3. The addition of lactacystin prevented the ARRDC3 
mediated decrease in ITGβ4 protein levels as determined by immunofluorescence and 
Western blots (Figure 3-8A&B). Since proteosome inhibition should not affect 
internalization, lactacystin treatment does not prevent the significant decrease in surface 
ITGβ4 as seen by flow cytometry (Figure 3-8C). To exclude the possibility of lysosomal 
contribution to the protein degradation, the experiment was repeated using chloroquin  
instead of lactacystin prior to infection. Chloroquin treatment did not prevent ITGβ4 
reduction after infection with adARRDC3 (Figure 3-9A&B). 
ARRDC3 directly interacts with activated ITGβ4 
A novel phosphorylation site on ITGβ4, serine-1424, was recently identified as 
important in hemidesmosome disassembly and shown to be enriched on the trailing edge 
of migrating cells (Germain et al., 2009). This phosphorylation, along with the 
phosphorylation of other serines, results in the disassembly of the hemidesmosome and 
mobilization of ITGβ4 to actin-rich protrusions (Germain et al., 2009; Rabinovitz et al., 
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1999; Rabinovitz et al., 2004; Wilhelmsen et al., 2007). To determine if this site is 
important in ARRDC3 mediated ITGβ4 internalization during breast cell migration, 
endogenous expression patterns of ITGβ4, ITGβ4-pS1424 and ARRDC3 were examined 
using confocal microscopy on migrating cancer cells.  ARRDC3 co-localizes with ITGβ4 
only on the lagging edge of the cell, where ITGβ4-pS1424 is enriched (Figure 3-10A). 
We then determined that ARRDC3 physically interacts with ITGβ4-pS1424 by 
endogenous immuno co-precipitation on lysates prepared from MDA-MB-231 cells pre-
treated with phosphatase inhibitors (Figure 3-10B).  Densitometric analysis demonstrates 
~70% of ITGβ4-pS1424 is immuno co-precipitated by an ARRDC3 antibody when 
compared to an ITGβ4 antibody. The densitometric ratio of precipitated pS1424/ITGβ4 is 
3.5 fold higher for the ARRDC3 immuno co-precipitation when compared to the ITGβ4 
immuno co-precipitation suggesting, ARRDC3 preferentially interacts with this 
“activated” (i.e. engaged in a signaling cascade) form of ITGβ4.  
As the regulation of ITGβ4 by ARRDC3 is dependent on the proteosome, we next 
wondered whether ARRDC3 interacts with ITGβ4 after it is targeted for degradation. In 
untreated MDA-MB-231 cells, there is an undetectable amount of ubiquitinated ITGβ4, 
even after ITGβ4 immuno co-precipitation. However, when cells were pre-treated with 
proteosome inhibitor lactacystin, higher molecular weight bands of ITGβ4 were detected 
after immuno co-precipitation with both ARRDC3 and ITGβ4 antibodies (Figure 3-10C). 
Immuno-blotting the same membranes for Ubiquitin revealed almost equal amounts of 
ubiquitinated- ITGβ4 is immuno co-precipitated with the ARRDC3 antibody when 
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compared to the ITGβ4 immuno co-precipitation (Figure 3-10C). This suggests that 
ARRDC3 maintains in complex with ITGβ4 after it is targeted for degradation. 
ARRDC3 specifically targets ITGβ4 
Cancer cells frequently have defects within vesicular trafficking and/or 
endocytotic pathways (reviewed in (Mosesson et al., 2008)). To demonstrate that 
ARRDC3 is specifically targeting ITGβ4, rather than stimulating generalized 
endocytosis, we examined a variety of cell surface proteins after cells (MDA-MB-231) 
were infected with either adGFP or adARRDC3. Analysis of non-permeabilized cells by 
flow cytometry shows that ARRDC3 over-expression did not affect surface levels of 
ITGβ1, CD44 and EpCam (Figure 3-11). These data indicate that ITGβ4 is specifically 
targeted by ARRDC3. 
Effects of ARRDC3 on in-vitro tumorigenicity is dependent on ITGβ4 
 To determine whether ITGβ4 was required to mediate the effects of ARRDC3 on 
cancer cell behavior, we used MDA-MB-435 (a cancer line which does not express 
ITGβ4) and MDA-MB-435+β4 cells (a daughter cell line engineered to over-express 
ITGβ4), to create lines with altered ARRDC3 levels and assayed for tumorigenicity. 
When analyzed by western blot, the inverse relationship between ARRDC3 and ITGβ4 
protein levels were maintained (Figure 3-12). 
 Similar to MDA-MB-231 cells, the MDA-MB-435+β4 cells showed marked 
changes in proliferation, migration, invasion and anchorage independent growth. Over-
expression of ARRDC3 in MDA-MB-435+β4 cells caused decreased proliferation and 
migration, while repression of ARRDC3 lead to increased proliferation and migration 
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(Figure 3-13A&B).  Soft agar assays again showed that over-expression of ARRDC3 
inhibits anchorage independent growth, while repressed ARRDC3 promotes 
tumorigenicity in the MDA-MB-435+β4 cells (Figure 3-13C&D). Cell invasion assays 
demonstrated a 50% decrease in the number of invasive cells in ARRDC3 over-
expressing cells whereas repression of ARRDC3 caused a two-fold increase (Figure 3-
13E).  In contrast to the ITGβ4-positive cell lines, ARRDC3 had marginal effects on the 
parental, ITGβ4-negative MDA-MB-435 cell line (Figure 3-13A-E). Interestingly, 
ARRDC3 over-expression reduced the tumorigenic properties of the MDA-MB-435+β4 
cells to that of the parental line. Altogether, these data show that ARRDC3 affects in-
vitro tumorigenicity, principally in an ITGβ4-dependent fashion. However, the data also 
shows that ARRDC3 also has an ITGβ4-independent effect on in-vitro tumorigenicity, 
but the physiological relevance of this pathway is unclear.  
ARRDC3 down-regulation and coordinate ITGβ4 up-regulation in human breast tumors 
Since there is an extensive connection between ITGβ4 and breast carcinogenesis, 
we examined protein levels of ARRDC3 and ITGβ4 in normal breast tissue and primary 
human breast cancers (invasive ductal carcinomas) obtained from UMass Cancer Center 
Tissue and Tumor Bank. As expected, ARRDC3 expression appeared to be inversely 
correlated to ITGβ4. It is interesting to note that moderate expression of ARRDC3 is not 
sufficient to completely abrogate ITGβ4 (Figure 3-14). 
We next examined expression of ARRDC3 and ITGβ4 in normal breast tissue 
sections using immuno-fluorescence. As expected, ITGβ4 positive cells were located in 
the basal layer of normal ducts.  Conversely, ARRDC3 was more highly expressed in 
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luminal cells and breast stroma (where ITGβ4 expression is negligible) but weakly 
expressed in basal cells (where ITGβ4 expression is highest) (Figure 3-15). 
The combination of our data and the current knowledge of ITGβ4 strongly 
suggested that repression of ARRDC3 would lead to a more aggressive/metastatic 
phenotype. To analyze the expression pattern of ARRDC3 in tumors, 52 human breast 
tumors of varied grade and ER/PR/HER2 receptor status (obtained from UMass Cancer 
Center Tissue and Tumor Bank) were used for ITGβ4 & ARRDC3 co-
immunofluorescence.  Expression of ARRDC3 was inversely correlated to tumor Grade 
(Table 3-1 & Figures 3-16 through 3-18). Within grade 1 tumors, 5/6 demonstrated high 
ARRDC3 staining while the outlier exhibited strong ITGβ4 staining (Figure 3-16). 
Interestingly, although expression of ARRDC3 varied greatly in grade 2 tumors, levels 
were inversely correlative to ITGβ4 expression (Figure 3-17). Grade 3 tumors generally 
expressed low or undetectable levels of ARRDC3. Only 2/22 grade 3 tumors displayed 
high expression of ARRDC3 (Figure 3-18). Although 11/52 tumors expressed no/low 
levels of ARRDC3 and ITGβ4, only 1/52 tumors had intense staining for both ARRCD3 
and ITGβ4. Matched primary/metastatic tumor samples showed a further repression of 
ARRDC3 level in the metastatic lesion (Figure 3-19).  
The combination of our data and the current knowledge of ITGβ4 strongly 
suggested that repression of ARRDC3 would lead to a more aggressive/metastatic 
phenotype. Overall, the data support the hypothesis that ARRDC3, probably through its 
effects on ITGβ4, acts as a regulator of breast cancer.  
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DISCUSSION 
In the present study, we describe a novel regulatory pathway involving the 
internalization and degradation of the cell surface protein ITGβ4, which has significant 
effects on breast cancer cell growth and tumorigenicity. We demonstrate that ARRDC3, 
previously identified by genetic screening as a potential tumor suppressor (Adelaide et 
al., 2007), is a new regulator of breast cancer progression. We show that ARRDC3 
directly binds to ITGβ4, specifically when phosphorylated at S1424, and ultimately leads 
to proteosome dependent degradation. The subsequent change in ITGβ4 protein levels 
significantly affects in-vitro tumorigenic properties such as proliferation, migration, 
invasion and growth in soft agar. In-vivo analyses demonstrate that ARRDC3 expression 
inversely correlates with tumor growth in nude mice and viability of tumor cells under 
stressed environments. Additionally, data from human breast cancer samples show that 
ARRDC3 expression is, in general, inversely correlated to ITGβ4 protein levels. 
ITGβ4 is part of a genetic signature correlated to basal-type breast cancer (Lu et 
al., 2008). It was therefore very interesting to note that ARRDC3 is part of a cluster on 
chromosome 5 deleted in 17% of the same basal-type breast cancer subset (compared to 
0% in luminal breast-cancers) (Adelaide et al., 2007). We found that ARRDC3 protein 
was low or absent in 5 of 11 human infiltrating ductal carcinomas of the breast, and these 
tumors had high levels of ITGβ4. Although we do not know the mechanism by which 
ARRDC3 is down-regulated within these tumors, we suspect that chromosome deletion is 
not the only cause of ARRDC3 deficits. Further genetic, epigenetic and mutational 
analyses of the ARRDC3 locus are needed to more fully investigate the transcriptional 
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regulation of ARRCD3 within tumors. All basal-like breast cancer samples we analyzed 
had little to no expression of ARRDC3 (Figure 3-20), suggesting that ARRDC3 may be 
inactivated by additional mechanisms other than chromosomal deletion. These data also 
suggest the loss of ARRDC3 is more critical in basal-type breast cancers, which typically 
express high levels of ITGβ4. Understanding the mechanism of ITGβ4 regulation by 
ARRDC3 may lead to improved therapies for this aggressive subset of breast cancer that 
currently has a very poor prognosis. However, it should be noted that neither ARRDC3 
repression nor ITGβ4 expression was exclusive to basal-like breast tumors meaning that 
potential therapies designed around this process would be beneficial to other cancer types 
as well. 
Interestingly, some tumors we evaluated maintained expression of both ARRDC3 
and ITGβ4. It is possible that the effects of ARRDC3 on ITGβ4 are simply dose 
dependent and moderate expression of ARRDC3 maintains intermediate levels of ITGβ4. 
Low or moderate levels of ARRDC3 may also allow for the recycling of ITGβ4 similar to 
the effects of -arrestin on GPCRs (Luttrell and Lefkowitz, 2002). It is worth speculating 
how one tumor we evaluated maintained high expression of both ARRDC3 and ITGβ4. If 
the pathway in which ARRDC3 targets ITGβ4 for degradation is somehow altered, it is 
possible that ARRDC3 could allow for the mobilization and recycling of ITGβ4 from 
hemidesmosomes at an increased rate. The presence of increased surface ITGβ4 we 
observed after treatment with a proteosome inhibitor may be evidence of such a 
mechanism (Figure 3-8C). This would facilitate the speed in which filamentous actin 
protrusions form, thus promoting tumor progression. However, further trafficking studies 
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are necessary to determine whether ITGβ4 is actively being recycled to the cell surface in 
the absence of degradation.  
ITGβ4 is the core component of hemidesmosomes which anchor keratin filaments 
within the cell to the basement membrane (Borradori and Sonnenberg, 1999; Jones et al., 
1998; Wilhelmsen et al., 2006). Hemidesmosomes mediate stable adhesion but are highly 
dynamic structures that can quickly disassemble under conditions in which detachment 
from the sub-strata is required, such as during cell migration or carcinoma invasion 
(Geuijen and Sonnenberg, 2002; Tsuruta et al., 2003). Previous investigations of the 
mechanism of hemidesmosome disassembly revealed the importance of several 
phosphorylation sites on ITGβ4 (Germain et al., 2009; Mainiero et al., 1996; Rabinovitz 
et al., 1999; Rabinovitz et al., 2004; Wilhelmsen et al., 2007). Our data reveal a novel 
intermediate in hemidesmosome disassembly during cell migration. After the cell 
receives migration stimuli, ARRDC3 directly interacts with ITGβ4 phosphorylated on 
S1424 by PKCα (Germain et al., 2009). As this phosphorylation event only occurs on the 
lagging edge of the cell, only ITGβ4 located there becomes endocytosed and sent to the 
proteosome, ultimately dissolving the hemidesmosome. This disruption of adhesion 
molecules at the lagging edge allows the cell to migrate. Although we demonstrated that 
ARRDC3 preferentially binds to the pS1424 form of ITGβ4, it is possible that other 
phosphorylation sites are mediators of ARRDC3 binding.  
Until recently, there have been relatively few investigations of the factors 
involved in integrin endocytosis. Internalization of integrins α5β1, αvβ6, αvβ3, α6β1 
have been associated with clathrin-mediated endocytosis (Caswell and Norman, 2008; 
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Ezratty et al., 2009), whereas integrins α5β1, αvβ3, α2β1 (Caswell and Norman, 2008; 
Shi and Sottile, 2008) have been connected to caveolae dependent endocytosis. Integrin 
α6β4 has been shown to associate with lipid rafts (Gagnoux-Palacios et al., 2003) 
suggesting that caveolae may play a role in internalization. However, not all integrin 
α6β4 was found associated with lipid rafts. Our data provides additional insight to the 
area of integrin endocytosis. Since ARRDC3 contains clathrin binding motifs it is 
possible that it functions by a clathrin-dependent mechanism although more investigation 
of the protein complexes within this pathway is needed. Lastly, ARRDC3 does not 
appear to interact with 1 integrins (Fig. 3-11) and because of the unique long 
cytoplasmic tail of ITGβ4, ARRDC3 is likely specific for this integrin.  
It has been hypothesized that during the progression from normal epithelium to 
invasive carcinoma, the function of ITGβ4 switches from a mechanical adhesive device 
into a signaling-competent receptor. In this case, ITGβ4 needs to be liberated from 
hemidesmosome where it can then be trafficked to actin-rich motility structures 
(filopodia and lamellae) (Lipscomb and Mercurio, 2005; Mercurio et al., 2001b; Santoro 
et al., 2003). Our findings highlight the importance of the ITGβ4-pS1424 site in this 
process as endogenous ARRDC3 co-localizes with this phosphorylated form of ITGβ4, 
likely causing internalization. ITGβ4-pS1424 has been identified as a critical residue in 
HD disassembly; however, MDA-MB-231 cells do not form HD. It is possible that the 
site is still phosphorylated prior to internalization of ITGβ4 regardless whether HDs need 
to be dissolved.  It is also possible that the real phosphorylation event increasing the 
ARRDC3/ITGβ4 interaction is caused by the same signals leading to ITGβ4-S1424 
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phosphorylation. It would be interesting to test whether SD (which mimics 
phosphorylation) and SA mutants (which cannot be phosphorylated) of residue S1424 
affect the ARRDC3/ITGβ4 interaction.  
It is clear from our data that ARRDC3 plays a role in the regulation of ITGβ4 
protein levels and likely contributes to the control of ITGβ4 function during breast cancer 
progression. The interaction between ARRDC3 and ITGβ4 may represent a new 
therapeutic target for basal-like breast cancers. Disruption of this interaction, by peptides 
or small molecules, may stabilize ITGβ4 in hemidesmosomes and block its growth and 
pro-survival effects. These data also highlight the importance of ITGβ4-blocking 
antibodies as a potential therapy. 
Our data does not exclude the possibility that ARRDC3 has an ITGβ4 
independent mechanism of action in cancer cells or in normal cells. The effects of 
ARRDC3 on cancer cells lacking ITGβ4 had marginal statistical significance and the 
overall effects were small (Figure 3-13). It is therefore unclear whether these effects are 
biologically significant. Considering its similarity to β-arrestins, ARRDC3 may also 
regulate G-protein coupled receptors (GPCRs). Possible targets could include 
Smoothened and Frizzled receptors (Class-6 GPCRs) or chemokine receptors (Class-1 
GPCRs); which all have extensive implications in cancer in addition to potential 
therapeutic targets. 
Although our data demonstrate tumor growth suppressor functions of ARRDC3 in 
breast cancer, it should not be taken for granted that this will readily translate to other 
tissues. ITGβ4 can play a dichotomous role in certain tissue types, either positively or 
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negatively regulating tumor progression (Giancotti, 2007; Rabinovitz and Mercurio, 
1996; Raymond et al., 2007).  The overall role of ARRDC3 in a specific cancer would 
depend on the role of the target proteins (like ITGβ4) in the cancer cells. 
In summary, our data identifies ARRDC3 as a novel regulator of breast cancer 
progression that targets ITGβ4 for internalization and proteosome dependent degradation. 
We reveal several oncogenic properties affected by changes in ARRDC3 expression and 
identify a correlation between ARRDC3 expression and human breast tumor 
grade/aggressiveness. Our research also raises additional questions. What other proteins 
work with ARRDC3 in ITGβ4 internalization? Is ARRDC3 involved in other steps of 
integrin trafficking? How is ARRDC3 regulated? What is the biological significance of 
possible ITGβ4-independent pathways? What other cancers show deregulated ARRDC3 
expression? Our data open several avenues of future research in cancer biology, which 
may ultimately lead to new treatment strategies. 
METHODS 
Cells and Reagents. MDA-MB-435 human breast carcinoma cells expressing wild-type 
ITGβ4 were generated previously (Shaw et al., 1997). MDA-MB-231 human breast 
carcinoma cells were obtained from the Lombardi Breast Cancer Depository 
(Georgetown University).  
siRNA Sequence and Transfection. Three different siRNA oligos were designed 
targeting the following sequences in ARRDC3: 1- AAACACGGCCTTCTATGCCA, 2- 
AAAGGCGGAACAATCTTGCAC, and 3- AATCTTGCACCAGTGAGTGCT. siRNA 
duplexes against these target sequences were ordered from Qiagen along with three 
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control target sequences. siRNA duplexes were transfected into cells using HiPerFect 
transfection reagent (Qiagen) following the manufacturer’s recommended protocol. For 
experiments shown in this paper, duplexes 1 and 3 were pooled for maximum knockdown 
of ARRDC3.  
Cloning and Generation of Stable Lines. pSuper vectors (Oligoengine) containing 
control shRNA (shCtl target sequence: TTCTCCGAACGTGTCACGT) and shRNAs 
targeting ARRDC3 (shARRDC3 target sequence A:GGCCTTGGCTACTACCAGT; 
shARRDC3 target sequence C: GCGTGGAATATTCACTAAT) were generated in our 
lab per manufacturers recommended protocol. Full length human ARRDC3 cDNA and 
Flag-LacZ fusion cDNA were cloned into the pBABE-puro expression vector (Addgene). 
Cells were transfected with Fugene HD (Roche) following manufacturers recommended 
protocol. Stable transformants were selected using puromycin and pooled. 
Adenoviral Preparation. Full length human ARRDC3 cDNA was initially cloned into 
pLEGFP (Clontech). The fragment containing ARRDC3+GFP (or GFP alone) was then 
cloned into Adeno-X LP CMV (Clontech) using the Adeno-X Expression System 2 kit 
(Clontech). Adeno-X maxi purification kit (Clontech) was used to isolate/purify the 
adenovirus. For all steps, the manufacturers recommended protocol was followed. The 
amount of virus needed for each cell type was determined empirically.  
Immunofluorescence. Cells were cultured on coverslips and fixed with acetone. Cells 
were permeabilized by incubating with PBS+Triton and blocked with 5% goat serum 
(Gibco). Coverslips were incubated with primary antibody (rabbit polyclonal ARRDC3 
(Abcam) and/or ITGβ4 439-9b (BD-Pharmingen)) for 2 hr at room temperature or 
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overnight at 4°C. After being washed, cells were then stained with secondary antibodies 
conjugated with either FITC or Texas-Red (Vector Laboratories) for 2 hours at room 
temperature. After washing, cover-slips were mounted on slides using Vectashield with 
DAPI (Vector Laboratories) and slides were analyzed using a fluorescence microscope. 
Wound Assay. 5x105 cells were evenly plated in a 6-well plate. 24 hours after plating, 
the 100% confluent cells were treated with 15µg/mL mitomycin C (Roche) for 90 
minutes at 37°C. The monolayer was scratched with a P200 pipette tip and washed 3 
times to remove floating cells. The wound closure was then monitored by digital 
photography. 
Growth in Soft Agar. 1.0 x 103 cells were suspended in 2mL of serum-containing 
medium containing 0.3% agar and overlaid on a 1mL base layer of 0.75% agar in six-
well plates. The soft agar was overlaid with complete medium (0.5 mL/well), which was 
changed every 2 days. After 3-4 weeks of incubation, viable colonies were stained by 
adding MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) into the 
covering media. Images were captured using bright-field microscopy and the number and 
size of the colonies were analyzed using ImageJ software. Only colonies with a diameter 
of >50μm were counted.  
Invasion. Matrigel invasion assays were performed as described previously using 6.5-
mm Transwell chambers (8-μm pore size, CoStar) (Shaw et al., 1997). After 4 hours, the 
cells that had invaded to the lower surface of the filters were fixed in methanol for 10 
minutes. The fixed membranes were mounted on glass slides using Vectashield mounting 
medium containing DAPI (Vector Laboratories). Invasion was quantified by counting the 
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number of stained nuclei in five independent fields in each transwell using ImageJ 
software. 
Xenograft Mouse Studies. Animals' care was in accordance with guidelines approved by 
IACUC. Cells were trypsinized, washed five times with sterile PBS, and re-suspended in 
35μL phenol red-free Matrigel immediately before injection. Female immuno-
compromised mice (nu/nu; National Cancer Institute) at 9 wk of age were anesthetized 
briefly with isofluorane and cells were injected into the #3 and #8 mammary fat pad (1 x 
106 cells per injection in 50μL of Matrigel, two injection sites per mouse). Estimated 
tumor volume was determined using the following formula: (4/3) π (1/2 x smaller 
diameter) 2 (1/2 x larger diameter). At the final time point, mice were euthanized using 
isoflourane and cervical dislocation. Final tumor volume (after dissection) was 
determined using the following formula: (4/3) π (1/2 x length) (1/2 x width) (1/2 x 
height).  
Tumor Analysis. All tumors were cut in half lengthwise. One piece was then imbedded 
in paraffin after formalin fixation, where the remaining piece was cut in two for fixation 
in O.C.T. and protein extraction. Sections of paraffin-embedded tumor were used for 
H&E staining, Ki67-IHC and TUNEL staining. All of the staining was performed by the 
DERC-Histology facility at UMass Medical School. 
Western Blot Analysis. Cell extracts containing equivalent amounts of total protein were 
resolved by SDS-PAGE and transferred to nitrocellulose membranes. Membranes were 
blocked for an hour using a 50 mM Tris buffer (pH 7.5) containing 0.15 mM NaCl and 
0.05% Tween 20 and 5% (w/v) Blocker (BioRad) in PBS+ Tween 20. Membranes were 
 109
incubated overnight at 4°C in the same buffer containing primary antibodies (rabbit pAB 
targeting ARRDC3 (Abcam ab64817) or rabbit pAB targeting ITGβ4 (505, a generous 
gift from Arthur Mercurio, UMMS Worcester, MA). Proteins were detected by enhanced 
chemiluminescence (Pierce). For phospho-immunoblots, the blocking buffer for the 
primary antibodies contained 5% (w/v) BSA. 
STATISTICAL ANALYSIS: All values in the present study were expressed as mean ± 
SEM unless otherwise noted. The significant differences between the groups were 
analyzed by a Student’s t test and a P value of <0.05 was considered significant. 
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Table 3-1: Expression of ARRDC3 in Human Breast Tumors 
ID HER2 ER PR Cancer Type Grade ITGβ4 ARRDC3
0630T - + weak Lobular Carcinoma 1 + +++
0832T - + - Ductal Carcinoma 1 + +++
0885T - + + Ductal Carcinoma 1 + ++
0909T - + weak Ductal Carcinoma 1 - +++
1334T - + + Lobular Carcinoma 1 +++ + 
1640T - + - Ductal Carcinoma 1 ++ ++
0199T + + + Ductal Carcinoma 2 ++ ++
0248T - + + Ductal Carcinoma 2 +++ + 
0327T + + + Ductal Carcinoma 2 ++ ++
0424T - + + Papillary Carcinoma 2 - + 
0448T - - - Ductal Carcinoma 2 +++ + 
0462T - + - Ductal Carcinoma 2 ++ ++
0480T - + + Ductal Carcinoma 2 + + 
0545T + + - Ductal Carcinoma 2 ++ ++
0576T - + - Ductal Carcinoma 2 +++ + 
0638T - + - Ductal Carcinoma 2 + ++
0837T weak - - Ductal Carcinoma 2 ++ + 
0884T - + - Lobular Carcinoma 2 ++ + 
0934T + - - Ductal Carcinoma IS 2 +++ + 
0960T + + + Ductal Carcinoma 2 + + 
1003T - + + Ductal Carcinoma 2 - ++
1099T - + - Ductal Carcinoma 2 + + 
1281T - + + Lobular Carcinoma 2 ++ - 
1376T - + + Lobular Carcinoma 2 +++ + 
1403T + + + Ductal Carcinoma 2 ++ ++
1404T - + + Lobular Carcinoma 2 +++ + 
1471L - + + Carcinoma 2 +++ + 
1471T - + + Ductal Carcinoma 2 +++ + 
1502T - + + Ductal Carcinoma 2 ++ ++
1569T - + + Ductal Carcinoma 2 + +++
0237T + - - Ductal Carcinoma 3 +++ - 
0316T + - + Ductal Carcinoma 3 +++ + 
0442T + - - Ductal Carcinoma 3 +++ + 
0454T - + + Lobular Carcinoma 3 +++ ++
0471T + + - Lobular Carcinoma 3 - + 
0489T - + + Lobular Carcinoma 3 + - 
0577T - + - Lobular Carcinoma 3 +++ + 
0690T - - - Ductal Carcinoma 3 - + 
0738T - - + Ductal Carcinoma 3 +++ + 
0839T - - - Ductal Carcinoma 3 - - 
0902T - - - Ductal Carcinoma 3 - ++
0957T - - - Ductal Adenocarcinoma 3 +++ + 
0959M - + - Carcinoma 3 - + 
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0959T - + - Ductal Carcinoma 3 + + 
1060T - + - Ductal Carcinoma 3 + + 
1097T weak + weak Ductal Carcinoma 3 ++ + 
1200T - - - Ductal Carcinoma 3 +++ - 
1342M - - - Ductal Carcinoma 3 +++ + 
1550T - + + Lobular Carcinoma 3 +++ + 
1623T - + + Ductal Carcinoma 3 +++ + 
1645T NT + + Lobular Carcinoma 3 ++ - 
1659T - + - Ductal Carcinoma 3 +++ + 
 
Table 3-1: Expression of ARRDC3 in human breast tumors. 52 human breast tumors were 
analyzed for ARRDC3 and ITGβ4 expression using immuno-fluorescence. ID refers to 
the UMass Tissue Bank tumor number. HER2, ER and PR statuses, cancer type and 
grade are those determined at the time of diagnosis. A – indicates no detectable 
expression, + is low expression, ++ is moderate expression and +++ is high expression. 
All samples were processed at the same time using the same master-mix of primary and 
secondary antibodies. Images from each sample were taken all on the same day using the 
same exposure times for each channel. Expression levels were determined by a person 
blinded to the sample information. 
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CHAPTER IV:  
Final Thoughts and Future Directions 
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The arrestin family of gene products was originally discovered as molecules that 
desensitize, or turn off, classical G protein-coupled receptor (GPCR) signaling 
(Hausdorff et al., 1990). Upon ligand binding, GPCRs are phosphorylated on many sites 
within an intracellular loop by GPCR kinases (GRKs). This modification leads to 
enhanced β-arrestin binding, physically blocking further signaling to G proteins and thus 
leading to receptor desensitization. Arrestins can also mediate internalization of 
receptors, leading to numerous physiological outcomes including receptor degradation, 
receptor recycling, and the generation of “signalosomes” where arrestins scaffold various 
proteins to potentiate distinct downstream signaling events (Figure 1-2). In recent years, 
these multifunctional adaptor proteins have also come to be appreciated as important 
mediators of core signaling pathways used in growth, differentiation, homeostasis and 
cancer. This includes the Hedgehog, Wnt, Notch, and TGFβ signaling pathways. Arrestin 
proteins are also key regulators of endocytosis: a complex cellular program, through 
which cells can regulate signaling, modulate adhesion and become polarized. 
The culmination of the data presented in my thesis underlines a mechanism by 
which ITGβ4 is regulated by ARRDC3. Through this mechanism, ARRDC3 can directly 
bind to ITGβ4, the phosphorylation of which seems to increase the affinity of the 
interaction. Preliminary data indicates that ARRDC3 preferentially binds to ITGβ4-
pS1424, although it is still unclear whether S1424 is the key site mediating the 
interaction. Upon this interaction, ITGβ4 becomes internalized and sent to the 
proteosome for degradation (Figure 4-1A). In a migrating cell these events appear to be 
restricted to the lagging edge of the cell on the basal layer, where the adhesion structures 
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are likely about to become disrupted (Figure 4-1B). This specific localization is likely 
critical in cell motility as cells cannot migrate without the disruption of these adhesion 
molecules. This regulation plays a critical role in all cellular functions affected by ITGβ4 
signaling; such as adhesion, migration, survival, invasion and proliferation. 
ARRDC3 deficient mice 
The importance of this regulation is best highlighted in our preliminary 
observations of ARRDC3 null mice. Although these mice develop normally, they display 
what we consider to be an “aging phenotype” compared to their wild-type littermates. 
This includes a loss of fur, decreased wound healing and a higher disposition towards 
lymphoma (Table 4-1). Mice heterozygous for ARRDC3 display a phenotype that is 
intermediate between the null and wild-type mice.  
Null mice exhibited patchy fur loss by 4 months of age and progressed as the 
mice aged (Figure 2-17). Additionally, these mice appeared more prone towards 
dermatitis and wounding (as reported by the animal facility veterinarians) than their wild-
type or even heterozygous littermates. Although fighting wounds are not uncommon in 
mice, a disproportionate number of ARRDC3 null and heterozygous mice needed to be 
euthanized due to their injuries compared to wild-type littermates (Table 4-1). In 
addition, in each of four separate mating cages (all containing one ARRDC3 null female, 
one ARRDC3 heterozygous female and one wild-type male) only the ARRDC3 null 
females presented with injuries on their hindquarter regions. This suggests that the loss of 
ARRDC3 renders the mouse either more likely to become wounded and/or decreases the 
rate at which the wounds are repaired. As the dermis is much thinner in the null mice 
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compared to wild-type littermates (Figure 2-18B), it is probable that ARRDC3 null mice 
wound more easily. However, this does not exclude the possibility that there is an 
impairment of the wound healing process. A decrease in the number of stem cells would 
affect homeostasis as well as prolong the wound healing process. Altogether, our 
observations support the notion that although ARRDC3 does not affect differentiation, its 
loss does allow for an increase in the migration of skin stem cells outside of the niche 
likely leading to an exhaustion of the stem cell pool and defective skin homeostasis. As 
these thoughts are generated from general observations outside of a well controlled 
experiment, definitive conclusions cannot be made. A formal study where a full-thickness 
skin biopsy is performed on each mouse and the wound-healing rates and histology are 
monitored would help to answer this question. 
Additionally, ARRDC3 null and heterozygous mice seemed to have an increased 
disposition towards developing cancer. All ARRDC3 null mice (not euthanized for lethal 
wounds) died before 11 months of age. Post-mortem necropsy of all mice revealed both 
spleenomegaly as well as large masses within (but not part of) the intestines. Histological 
analyses of the spleen and the masses found an abundance of plasma cells indicating 
these mice suffered from a lympho-proliferative disease, most likely multiple myeloma 
based on the presence of “clock-face” cells (Figure 4-2A&B). This predisposition 
towards lymphoma was also evident in the heterozygous mice, although survival for this 
genotype exceeded that of the null mice. However, it is impossible to distinguish the 
affects of ARRDC3 from the normal pathology of 129; B6 mice. Studies indicate that 
only 44.5% of 129;B6 mice are alive at 2 years and 54% of these mice develop 
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lymphoma (Haines et al., 2001). However, the 129; B6 mice had an average disease 
latency of 15 months whereas the ARRDC3 null mice all developed lymphoma before 1 
year. This decreased latency suggests a tumor suppressive role for ARRDC3, but as wild-
type littermates were not monitored for lymphoma, we cannot be sure. Interestingly, a 
single 19-month old ARRDC3 heterozygote generated a mass in the mammary tissue. 
Histological analysis revealed that this mass was a well-differentiated mammary adeno-
carcinoma (Figure 4-2C). However, as mammary carcinomas can spontaneously form in 
<1% of wild-type mice (albeit at a latency of 24+ months), it is possible that the 
formation of this tumor is unrelated to ARRDC3 deficiency. The analysis of a larger 
cohort of ARRDC3 -/- and ARRDC3 +/- on a pure background is needed to determine 
whether these mice are more cancer-prone. 
Impact in hemidesmosome regulation & cell migration 
While the ARRDC3 induced changes in ITGβ4 protein levels are modest, the 
affects on cell motility are pronounced (Figures 2-9A & 2-13). This suggests the balance 
between stationary and motile states of both skin stem cells and cancer cells is delicate. 
Motility has significant implications for both cancer and stem cells. Stem cells need to 
stay within the growth and differentiation restricted environment of the niche whereas 
increased migration of cancer cells is a hallmark characteristic of metastasis. 
Hemidesmosomes (HDs) are dynamic structures which are constantly turning over, even 
in resting cells (Daisuke Tsuruta, 2003; Geuijen and Sonnenberg, 2002). This 
phenomenon is thought to keep the cell in a “primed” state allowing it to respond more 
quickly to migratory stimuli. It is likely that the internalization of ITGβ4 by ARRDC3 is 
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part of the normal machinery involved in HD turnover. Our data showing the co-
localization of ARRDC3 with ITGβ4 and plectin on the basal layer of resting cells 
supports this hypothesis (Figure 2-8C&D). It would be interesting to investigate whether 
the ARRDC3 and plectin co-localization also becomes polarized within a migrating cell.  
It is important to remember that our studies examining the localization of ITGβ4 
and ARRDC3 (for both resting and migrating cells) were performed using cells cultured 
in their cell-line specific media. Although this media contains EGF, the concentration 
(10ng/mL) is 10-fold lower than that used when stimulating cells to undergo HD 
disassembly (Germain et al., 2009; Rabinovitz et al., 2004; Wilhelmsen et al., 2007). To 
study the role of ARRDC3 in hemidesmosome disassembly further, the cells would need 
to be stimulated by concentrations of EGF closer to 100ng/mL and re-analyzed using 
either proximity ligation analysis (PLA) or immuno-fluorescence (IF).  
It would be interesting to evaluate the importance of the S1424 site in ITGβ4 
regulation by ARRDC3. Our data suggest that phosphorylation on this site enhances the 
interaction between ARRDC3 and ITGβ4 (Figures 2-8B, 2-14B, and 3-10A&B). 
However, the fragment of ITGβ4 used in the original yeast-2 hybrid screen only included 
amino acids 987-1120 (Figure 4-3A). It is possible that S1424 provides a binding site for 
another protein that either hinders ARRDC3 interaction when un-phosphorylated or 
stabilizes the interaction when phosphorylated. It would also be interesting to test 
whether the phosphorylation status of S1356, S1360, and S1364 impact ARRDC3 
mediated internalization of ITGβ4. These sites are phosphorylated in response to EGF (a 
key growth factor in HD disassembly as well as cell migration) and are crucial in HD 
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disassembly (Rabinovitz et al., 2004; Wilhelmsen et al., 2007). If ARRDC3 plays a role 
in normal HD disassembly, it would be logical that the phosphorylation of these sites also 
affect the affinity between ARRDC3 and ITGβ4. However, it is possible that ARRDC3 
can only interact with ITGβ4 after it is liberated from the HD therefore the increased 
ARRDC3/ITGβ4-pS1424 interaction is only correlative.  
It is also feasible that these phosphorylation events are effects of ARRDC3 
binding rather than vice versa. For other family members, the phosphorylation of the 
receptor allows for the binding of the arrestin at the site of phosphorylation (Gurevich 
and Gurevich, 2006b; Luttrell and Lefkowitz, 2002). Arrestins can then act as scaffolding 
proteins or bridging factors which recruit other signaling molecules including kinases 
(Buchanan and DuBois, 2006; Gurevich and Gurevich, 2006a). ARRDC3 may be the 
molecule responsible for recruiting PKC and PKA (the kinases responsible for 
phosphorylating S1356, S1360, S1364 and S1424) to the cytoplasmic tail of ITGβ4 
(Germain et al., 2009; Rabinovitz et al., 1999; Rabinovitz et al., 2004; Wilhelmsen et al., 
2007). It is possible that the ARRDC3-interaction region on ITGβ4 is upstream of all of 
these key phosphorylation sites to allow access for any kinases it recruits (Figure 4-3B). 
We know that phosphatase inhibition allowed us to see the interaction between ARRDC3 
and ITGβ4, but more specific mutational analysis would need to be performed to know 
which sites are critical for binding. 
Potential Regulation of ARRDC3 
 Further insight into the transcriptional regulation of ARRDC3 is another area of 
interest. One study suggests that ARRDC3 is under the control of the Forkhead 
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transcription factor family member STOX1 (Rigourd et al., 2008). It is therefore possible 
that other Forkhead family members can also regulate ARRDC3. Some of these have also 
been found to repress cancer progression (Ahmad et al., 2009; Rayoo et al., 2009; Zhang 
and Sun, 2009), whereas others seem to promote cancer progression (Han et al., 2008; 
Storz et al., 2009). 
 As the surface expression of ITGβ4 increases in a hypoxic environment (Yoon et 
al., 2005), we sought out to investigate whether ARRDC3 was repressed in hypoxia 
versus normoxia. Contrary to our expectations, ARRDC3 mRNA actually increased in 
cells cultured in a hypoxic environment (Figure 4-4). This data corresponded to 
information found on Oncomine (Figure 4-4). When we examined the ARRDC3 
promoter, we found 2 conserved HRE (hypoxia response elements). However, chromatin 
immuno-precipitation would need to be performed to determine whether ARRDC3 is 
actually a direct target of HIF1. Regardless, it is difficult to reconcile how increased 
ITGβ4 surface expression occurs after an increase in ARRDC3 mRNA. This suggests that 
ARRDC3 has a role in ITGβ4 regulation beyond degradation. 
Integrin Recycling 
We show that ARRDC3 promotes the internalization of ITGβ4 and subsequent 
degradation via the proteosome (Figures 2-11C & 3-8C). It is worth speculating how 
some of the tumors analyzed maintained expression of both ARRDC3 and ITGβ4 (Figure 
3-14). It is possible that the effects of ARRDC3 on ITGβ4 are simply dose dependent and 
moderate expression of ARRDC3 maintains intermediate levels of ITGβ4. Low or 
moderate levels of ARRDC3 may also allow for the recycling of ITGβ4 similar to the 
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effects of -arrestin on GPCRs (Luttrell and Lefkowitz, 2002). It is conceivable that 
lower levels of ITGβ4 would indicate less ligand-independent signaling therefore less 
stimulated ITGβ4 needed to endocytose. However, this would not explain the one tumor 
we evaluated which maintained high expression of both ARRDC3 and ITGβ4 (Table 3-
1). If the pathway in which ARRDC3 targets ITGβ4 for degradation is somehow altered, 
ARRDC3 expression may allow for an increase in the mobilization rate (and hence 
recycling rate) of ITGβ4. This would facilitate the speed in which filamentous actin 
protrusions form, thus promoting tumor progression. However, further trafficking studies 
are necessary to determine whether ITGβ4 is actively being recycled to the cell surface in 
the absence of degradation. 
Integrin Trafficking 
Although our data clearly demonstrates that ARRDC3 actively promotes the 
internalization of ITGβ4, it is unclear whether it is directly involved in the trafficking to 
the proteosome. Although over-expression of ARRDC3 leads to degradation of ITGβ4, it 
is possible that there is a point after internalization where other signals from the cell 
could contribute to its fate; either degradation or recycling. The ubiquitination state of 
ITGβ4 likely plays a role in this fate decision. We show that ITGβ4 in complex with 
ARRDC3 is ubiquitinated (Figure 3-10C). As arrestins can behave as scaffolding 
molecules, ARRDC3 may potentially play a role in the recruitment of the ubiquitination 
machinery necessary for modifying ITGβ4. The C-terminus of ARRDC3 contains a 
PPXY motif that can interact with HECT ubiquitin ligases such as Smurf1, WWP1/2, 
Itch and the NEDD family proteins (Ingham et al., 2004; Martin-Serrano et al., 2005; 
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Sangadala et al., 2007). As with the integrin recycling, more definitive trafficking studies 
would need to be performed to determine whether ARRDC3 plays a role beyond the 
internalization of ITGβ4. 
Although our data demonstrates that ARRDC3 over-expression leads to the 
degradation of ITGβ4, this is not necessarily its role in the cell when expressed at 
endogenous levels. It is possible that ARRDC3 also plays a role in re-localizing ITGβ4 to 
either the cell surface or the leading edge of the cell where it helps form and stabilize 
motility structures (filopodia and lamellae) (Lipscomb and Mercurio, 2005; Mercurio et 
al., 2001b; Rabinovitz and Mercurio, 1997; Santoro et al., 2003). When treated with a 
proteosome inhibitor, cells over-expressing ARRDC3 have slightly higher ITGβ4 surface 
protein levels compared to untreated cells; suggesting at least a small fraction of 
internalized protein is returned to the cell surface when it cannot be degraded (Figure 2-
11C & 3-8C). Additionally, the basal ITGβ4 and apical ARRDC3 staining patterns seen 
on the leading edge of the cells suggests a role beyond degradation (Figure 2-14A). 
Although we show that ARRDC3 and ITGβ4 directly interact, it is important to 
realize that we do not show whether any of the ARRDC3-induced affects on ITGβ4 are a 
result of this interaction. Although it is probable that ARRDC3 and ITGβ4 need to 
physically interact to cause internalization and degradation, we would need to generate an 
ITGβ4-binding deficient form of ARRDC3 and test whether it affects ITGβ4 protein 
levels and cellular process like migration. This mutant could also be used to determine 
the relevance of other ARRDC3 targets in cell migration, invasion, etc. 
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It is also interesting to speculate what proteins (besides ARRDC3) make up the 
machinery involved in ITGβ4 regulation. Until recently, there have been relatively few 
investigations of the proteins involved in integrin endocytosis. Internalization of integrins 
α5β1, αvβ6, αvβ3, α6β1 have been associated with clathrin-mediated endocytosis 
(Caswell and Norman, 2008; Ezratty et al., 2009), whereas integrins α5β1, αvβ3, α2β1 
(Caswell and Norman, 2008; Shi and Sottile, 2008) have been connected to caveolae 
dependent endocytosis. ITGβ4 has been shown to compartmentalize in lipid rafts to 
permit association with a palmitoylated Src family kinase (allowing for mitogenic 
signaling) (Gagnoux-Palacios et al., 2003) suggesting that caveolae may play a role in 
internalization. However, our data suggested the endocytosis of ITGβ4 is through a 
clathrin-dependent pathway (Figure 2-7C). Further evidence supporting our data is the 
clathrin binding motifs within ARRDC3. However, this does not exclude the possibility 
that ARRDC3 can promote non-clathrin mediated endocytosis. Also, as not all integrin 
α6β4 is found associated with lipid rafts, it is possible that another protein may be 
responsible for either internalizing ITGβ4 while in lipid rafts or removing ITGβ4 from 
the lipid raft. Since the mechanism of internalization is thought to contribute to the fate of 
the endosome, ARRDC3 might differentially co-localize with clathrin or caveolin in 
response to different stimuli. As our data only looked at normal resting cells, it is possible 
that we would see a different set of machinery in migrating or cancer cells. Further 
experiments would need to be done to investigate this possibility.   
Implications in Cancer 
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It has been hypothesized that the function of ITGβ4 switches from a mechanical 
adhesive device into a signaling-competent receptor during the progression from normal 
epithelium to invasive carcinoma (Lipscomb and Mercurio, 2005; Mercurio et al., 2001b; 
Santoro et al., 2003). It would be interesting to see if expression of ARRDC3 inhibits or 
promotes this process. Relatively high expression of ARRDC3 in grade one tumors 
suggests that its loss is not necessary for tumorigenesis, although it seems to turn off as 
the tumor progresses. It is clear from our data that ARRDC3 plays a role in the regulation 
of ITGβ4 protein levels and likely contributes to the control of ITGβ4 function during 
breast cancer progression. However, as we are unclear whether ARRDC3 plays a role in 
the trafficking and/or recycling of ITGβ4, it is hard to determine whether its expression in 
the early stages of cancer would be beneficial or detrimental. This could be determined 
by crossing our ARRDC3 null and heterozygous mice to a mammary tumor model (such 
as Brca1fl/fl; MMTV-Cre; Trp53+/−) and determine if there is any affect on either the 
penetrance or the latency of disease. Approximately 73% of these mice form mammary 
carcinomas by 6-8 months of age allowing room to show both acceleration and inhibition 
of carcinogenesis (Xu et al., 1999).  
Another question raised by our experiments concerns the effect of ARRDC3 
expression on metastasis. Although we examined the lungs of mice from the xenograph 
study and only found micro-metastases in the shARRDC3 tumors, we cannot draw any 
conclusions as the tumors from each sub-line were of different sizes. It is possible that if 
permitted to grow to as large a volume, the tumors with over-expressed ARRDC3 would 
metastasize to the same extent. Additionally, the MMTV-PyMT transgenic mice form 
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highly aggressive tumors which metastasize to the lungs (Guy et al., 1992); crossing them 
with the ARRDC3 -/- null mice would help to answer whether ARRDC3 expression 
affects metastasis. However, the combined knowledge that over-expression of ARRDC3 
decreased in-vitro invasion, repressed ARRDC3 promoted in-vitro invasion and ITGβ4 is 
known to promote metastasis; it is probable that ARRDC3 is a negative regulator of 
metastasis as well. 
The interaction between ARRDC3 and ITGβ4 may represent a new therapeutic 
target for basal-like breast cancers that can be manipulated by peptides or small 
molecules. These data also highlight the importance of ITGβ4-blocking antibodies as a 
potential therapy in breast cancer. However, it should not be taken for granted that this 
will readily translate to other tissues. ITGβ4 can play a dichotomous role in various tissue 
types, either positively or negatively regulating tumor progression (Giancotti, 2007; 
Rabinovitz and Mercurio, 1996; Raymond et al., 2007).   The overall role of ARRDC3 in 
a specific cancer would depend on the role of its target protein(s) in that particular cancer 
type. 
 Another question arising from our human breast cancer analysis concerns the 
significance of genes differentially expressed in cancer stroma versus the malignant cells. 
When assigning scores for ARRDC3 and ITGβ4 expression, only the malignant glands 
were evaluated. A serial section for each sample was used for H&E analysis and this was 
referenced throughout the scoring to ensure only tumor tissue was being examined. 
Interestingly, the tumor stroma, especially in grade 3 tumors, tended to express higher 
levels of ARRDC3, even when the breast cancer cells did not (an example can be seen in 
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Figure 3-18). Although it is possible the staining is non-specific, I feel that is unlikely as 
not all tumor stroma stained positive for ARRDC3. Without further knowledge of the 
roles for ARRDC3 beyond that of ITGβ4 regulation, it is impossible to hypothesize the 
significance of its expression in stroma. It would be interesting to test whether ARRDC3 
null mice show changes in in vivo tumor formation in a breast cancer xenograph study 
when compared to wild type mice. 
 Interestingly, although ARRDC3 is preferentially lost in basal like breast cancers 
(Adelaide et al., 2007), data obtained from Oncomine revealed that basal like breast 
cancers demonstrate no change in ARRDC3 mRNA levels when compared to non-basal 
like cancers (Figure 4-5). This could indicate that the loss of ARRDC3 does not influence 
the tumor classification. However, it is also possible the samples used in the microarray 
analysis were not purely cancer cells, but had contaminating stroma. In order to 
definitively answer this question, tumors with known classification would need to be 
analyzed for ARRDC3 expression using either IHC/IF on tumor sections or real-time 
PCR from laser-captured tumor cell RNA. 
Other potential targets of ARRDC3 
Our data does not exclude the possibility that ARRDC3 has targets other than 
ITGβ4 in either cancer cells or in normal cells. ARRDC3 could be similar to β-arrestins 
(which have a vast array of targets) or visual arrestins (which are only responsible for 
regulating rhodopsin in photoreceptors of the eye). As the expression of ARRDC3 is not 
nearly as restricted as the expressions of visual arrestins (Figure 2-3A); I believe it is 
probable that targets other than ITGβ4 exist. Supporting this notion, we see statistically 
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significant effects on tumorigenicity when modulating ARRDC3 in cancer cells lacking 
ITGβ4 (Figure 3-13). Unfortunately, as overall effects were small, it is unclear whether 
these targets are biologically significant in cancer. Considering its similarity to β-
arrestins, ARRDC3 may also regulate G-protein coupled receptors (GPCRs). Possible 
targets could include Smoothened and Frizzled receptors (Class-6 GPCRs) or RhoA/C 
(Class-1 GPCRs); which all have extensive implications in cancer and skin stem cells. 
Although our data does not exclude the possibility that other integrins are regulated by 
ARRDC3, this is unlikely. Our data shows that ARRDC3 expression does not appear to 
affect 1 integrin (Fig. 3-11). Additionally, the region in which ARRDC3 interacts with 
ITGβ4 is within the unique long cytoplasmic tail which does not share homology with 
other integrins. 
Final Thoughts 
 The research presented in this thesis provides insight into the regulation of ITGβ4 
and how it affects systems within stem cell and cancer biology. This research lays the 
groundwork for a lot of future research as well. ARRDC3 may be critical for maintaining 
adult stem cells (other than skin) within their niche. Also, any protein with a potential 
role in aging is of profound interest because it may provide information into the ultimate 
deterioration of organ systems. Additionally, ARRDC3 may be the key in therapeutic 
targeting of ITGβ4 in cancer; however a deeper understanding of the mechanism in 
which it regulates ITGβ4 is needed before this potential can be realized.  
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 Number DOB Genotype DOD Age (Days) Comments 
71 22-Jan-08 +/+ 4-Jan-10 713   
72 22-Jan-08 +/+ 4-Jan-10 713   
73 22-Jan-08 +/+ 4-Jan-10 713   
74 22-Jan-08 +/+ 4-Jan-10 713   
75 22-Jan-08 +/+ 4-Jan-10 713   
76 22-Jan-08 +/+ 4-Jan-10 713   
77 22-Jan-08 +/+ 4-Jan-10 713   
78 22-Jan-08 +/+ 4-Jan-10 713   
79 22-Jan-08 +/+ 4-Jan-10 713   
80 22-Jan-08 +/- 16-Sep-09 603 dermatitis 
81 22-Jan-08 +/- 15-Feb-09 390 dead from fighting wounds 
82 22-Jan-08 +/- 26-Nov-08 309 dead from fighting wounds 
83 22-Jan-08 +/- 13-Mar-09 416 found dead; cancer 
84 22-Jan-08 +/- 23-Nov-09 671 found dead; cancer 
85 22-Jan-08 +/- 6-Jun-09 501 dead from fighting wounds 
86 3-Mar-08 +/- 2-Dec-09 639 breast cancer 
87 3-Mar-08 +/- 30-Aug-09 545 found dead 
88 3-Mar-08 +/+ N/A N/A   
89 3-Mar-08 -/- 7-Jul-08 126 dead from fighting wounds 
90 3-Mar-08 -/- 8-Jul-08 127 dead from fighting wounds 
91 3-Mar-08 +/+ 11-Jan-10 679   
92 3-Mar-08 +/- 6-Apr-09 399 found dead 
93 3-Mar-08 +/+ 11-Jan-10 679   
94 3-Mar-08 -/- 12-Dec-08 284 found dead; cancer 
95 3-Mar-08 -/- 29-Sep-08 210 found dead; cancer 
96 3-Mar-08 +/- N/A N/A dermatitis & fur loss 
97 3-Mar-08 +/- N/A N/A dermatitis & fur loss 
98 3-Mar-08 +/+ N/A N/A   
99 3-Mar-08 +/+ N/A N/A   
100 3-Mar-08 +/+ 1-Dec-08 273 dead from fighting wounds  
101 3-Mar-08 +/+ N/A N/A   
102 3-Mar-08 +/- N/A N/A dermatitis 
103 3-Mar-08 +/- N/A N/A dermatitis 
104 3-Mar-08 -/- 22-Oct-08 233 found dead; cancer 
105 3-Mar-08 +/- N/A N/A dermatitis 
106 3-Mar-08 +/+ N/A N/A   
107 3-Mar-08 +/- N/A N/A fur loss 
108 3-Mar-08 +/- N/A N/A fur loss 
109 3-Mar-08 +/+ N/A N/A   
110 8-Mar-08 +/- N/A N/A fur loss 
111 8-Mar-08 +/- 1-Dec-08 268 dead from fighting wounds 
112 8-Mar-08 +/- 1-Dec-08 268 dead from fighting wounds 
113 8-Mar-08 +/- N/A N/A fur loss 
114 8-Mar-08 +/+ N/A N/A   
115 8-Mar-08 +/+ N/A N/A   
116 8-Mar-08 +/+ N/A N/A   
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Table 4-1: Loss of ARRDC3 in mice appears to have an aging phenotype. Four different 
litters of ARRDC3 wild type, heterozygous and null mice were observed over a 
phenotype. All ARRDC3 null mice lacked whiskers from birth, yet ARRDC3 
heterozygous mice did not appear to have this defect. Mice lacking ARRDC3 seemed 
more prone to develop cancer (specifically lymphoma) or obtain lethal wounds from 
fighting. All mice are on a 129; B6 background. 
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Abstract: 
The most common translocation in childhood T cell acute lymphoblastic leukemia 
(T-ALL) involves the LMO2 locus, resulting in ectopic expression of the LMO2 gene in 
human thymocytes. The LMO2 gene was also activated in 3/20 patients with X-linked 
Severe Combined Immune Deficiency (X-SCID) treated with gene therapy due to 
retroviral insertion in the LMO2 locus. The LMO2 insertions predisposed these children 
to T-ALL, yet how LMO2 contributes to T cell transformation remains unclear. The LIM 
domain containing LMO2 protein regulates erythropoiesis as part of a large 
transcriptional complex consisting of LMO2, TAL1, E47, GATA1 and LDB1 that 
recognizes bipartite E box-GATA1 sites on target genes. Similarly, a 
TAL1/E47/LMO2/LDB1 complex is observed in human T-ALL and Tal1 and Lmo2 
expression in mice results in disease acceleration. To address the mechanism(s) of 
Tal1/Lmo2 synergy in leukemia, we generated Lmo2 transgenic mice and mated them 
with mice that express wild type Tal1 or a DNA binding mutant of TAL1. Tal1/Lmo2 
and MutTAL1/Lmo2 bitransgenic mice exhibit perturbations in thymocyte development 
due to reduced E47/HEB transcriptional activity and develop leukemia with identical 
kinetics. These data demonstrate that the DNA binding activity of Tal1 is not required to 
cooperate with Lmo2 to cause leukemia in mice and suggest that Lmo2 may cooperate 
with Tal1 to interfere with E47/HEB function(s). 
Introduction: 
LMO2 was first implicated in leukemogenesis in 1992 when found associated 
with a t(11;14)(p13;q11) and t(7;11)(q34;p13) chromosomal translocations (Boehm et al., 
1990; Garcia et al., 1991). The LMO1 and LMO2 proteins are found expressed in human 
T-ALL and LMO proteins are co-expressed in approximately 80% of TAL1+ human T-
ALL patients (Ferrando et al., 2002; Rabbitts, 1994; Wadman et al., 1994). Interest in 
LMO2-mediated leukemogenesis was reignited in 2002, when 4/5 children in 2 X-SCID 
gene therapy trials developed T-ALL due to retroviral insertion in the LMO2 
locus(Hacein-Bey-Abina et al., 2003a; Hacein-Bey-Abina et al., 2003b). Two leukemic 
patients exhibited evidence of TAL1 activation and 3 patients developed NOTCH1 
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mutations (Hacein-Bey-Abina et al., 2008; Howe et al., 2008). Studies in mouse T-ALL 
models revealed that Tal1 and Lmo proteins cooperate to cause leukemia in mice (Larson 
et al., 1996; Wadman et al., 1994), but precisely how LMO proteins contribute to 
leukemogenesis remains unclear.  
LMO2 is part of the “LIM only” family of proteins that are thought to serve as 
bridging factors in transcriptional complexes (Wadman et al., 1997). LIM-domains are 
cysteine-rich zinc-binding domains that are structurally similar to DNA-binding GATA 
finger domains; however, currently there is no evidence to suggest that LMO proteins 
bind DNA. LMOs are thought to mediate protein:protein interactions via their LIM 
domains and evidence suggests that LMOs act as transcriptional co-regulators. There are 
4 human LMO proteins (LMO1-4) and all four LMO proteins have been associated with 
oncogenesis (Aoyama et al., 2005; Fisch et al., 1992; Visvader et al., 2001).  
LMO2 is a nuclear protein that in erythroid cells forms a multi-protein complex 
which includes TAL1, E47, GATA-1, and LDB1 (Valge-Archer et al., 1994). These 
proteins form a functional transcriptional complex and recognize a bipartite DNA 
sequence consisting of an Ebox and a GATA site separated by one helix turn (Wadman et 
al., 1997). The Tal1/E47/Lmo2/Ldb1/GATA-1 complex regulates the expression of genes 
important in erythroid or megakaryocytic differentiation, including p4.2, glycophorin A, 
c-kit, p21CIP and the transcription factors Gfi-1b and eklf (Goardon et al., 2006; Krosl et 
al., 1998; Lahlil et al., 2004; Lecuyer et al., 2002; Xu et al., 2006). Lmo2 is thought to 
bridge the TAL1/E47 heterodimer to GATA-1, and by mechanisms not fully understood, 
enhance transcription (Xu et al., 2003). Based on their roles in regulating gene expression 
during hematopoiesis, Tal1 and Lmo2 have been thought to contribute to leukemia by 
transactivating the expression of genes such as retinaldehyde dehydrogenase, the 
transmembrane protein TALLA1, the receptor tyrosine phosphatase IA2, cyclin D2, heat 
shock cognate 73 and a bub-like gene (Davenport et al., 2000; Ono et al., 1997).  
An alternative model posits that in leukemic cells the Tal1/Lmo2 complex 
interferes with the transcriptional activity of E47/HEB, by sequestering E47 and HEB 
proteins and/or by recruiting co-repressors to E-box regulated loci (Herblot et al., 2000; 
 182
O'Neil et al., 2004). The E47/HEB complex directs the expression of several genes 
essential for proper lymphoid development including the preTα chain of the pre-TCR, the 
Rag1 and Rag2 recombinases, CD3, CD4, CD5 and the T cell receptor α/β 
genes(Greenbaum and Zhuang, 2002a; Greenbaum and Zhuang, 2002b). A HEB or E47 
deficiency disrupts thymocyte development and E47-deficient mice are predisposed to 
the development of T cell leukemia (Bain et al., 1997). Our published work provides 
genetic evidence to support the inhibition model of TAL1-mediated leukemogenesis. We 
demonstrate that a DNA binding mutant form of TAL1 (R188G;R189G) (referred to here 
as mutTAL1) is able to induce T-ALL-like disease in mice and T cell leukemogenesis is 
accelerated when Tal1 is expressed on an E2A or HEB heterozygous background (O'Neil 
et al., 2001; O'Neil et al., 2004). Moreover, the functions of Tal1 in early hematopoietic 
development also do not appear to require the DNA binding properties of Tal1 (Schlaeger 
et al., 2004). More recently, the ETO-2 repressor has been identified as a novel 
component of the TAL1/LMO2 complex in erythroid cells (Goardon et al., 2006). Thus, 
Tal1/E47 or HEB/Lmo2 complexes may also actively repress the expression of E-box 
containing genes during normal erythroid differentiation and in leukemia. 
To determine the molecular basis of the observed Tal1/Lmo2 synergy and to 
distinguish between the transcriptional activation and inhibition models, we asked 
whether the DNA binding properties of Tal1 were required to collaborate with Lmo2 to 
cause T cell leukemia in mice. To test this model, we generated bitransgenic mice co-
expressing LMO2 with wild type Tal1 or with a DNA binding TAL1 mutant. We 
observed disease acceleration in both the Tal1/Lmo2 and mutTAL1/Lmo2 transgenic 
mouse lines, indicating that the DNA binding properties of TAL1 are not required to 
cooperate with Lmo2 to cause disease in mice. Moreover, thymocyte development was 
inhibited in pre-leukemic Tal1/Lmo2 and mutTAL1/Lmo2 mice due to reduced 
expression of E47/HEB-regulated genes important for thymocyte differentiation. These 
data indicate that Lmo2 may accelerate Tal1-mediated leukemogenesis by enhancing the 
sequestration and/or inhibition of the E47/HEB heterodimer. 
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Results and Discussion: 
Generation of transgenic mice expressing a DNA binding mutant of TAL1 and Lmo2  
Approximately 80% of TAL1 expressing T-ALL patients also express LMO 
proteins (Ferrando et al., 2002). Tal1 and Lmo expression in the mouse results in 
dramatic acceleration of disease (Aplan et al., 1997; Larson et al., 1996). To determine 
how Lmo2 contributes to TAL1-mediated leukemogenesis and to understand the basis for 
the TAL1 and LMO oncogenes cooperativity, we asked whether the DNA binding 
properties of TAL1 were required to cooperate with Lmo2 to cause disease in mice. To 
express both oncogenes in developing mouse thymocytes, we generated transgenic mouse 
lines where the mouse Lmo2 cDNA was expressed under the control of the proximal lck 
promoter (Figure 1A). The 3´ untranslated regions of this construct contain introns, exons 
and the poly A addition site of the human growth hormone gene (Abraham et al., 1991). 
The prox lck Lmo2 construct was microinjected into the pronuclei of fertilized FVB/N 
oocytes. Sixteen founder mice were identified initially by Southern blot analysis and two 
founder lines (Fo5 and 19) with variable expression levels were expanded for further 
study (Figure 1B).  
The Lmo2 transgenic mouse lines were mated with transgenic mice expressing 
wild type Tal1 or a DNA binding mutant of TAL1. The DNA binding mutant mice 
express a form of TAL1 where the contact residues of the basic DNA binding domain, 
arginine 188 and 189 have been mutated to glycines (designated R188G;R189G) (Hsu et 
al., 1994). This mutant form of TAL1 heterodimerizes with E47 or HEB proteins but fails 
to stably bind E box binding sequences in-vitro and in vivo (Hsu et al., 1994; O'Neil et 
al., 2001). Like Tal1 transgenic mice, expression of a TAL1 DNA binding mutant 
perturbs thymocyte development and approximately half of the mice develop a T-ALL-
like disease (O'Neil et al., 2001).  
To determine whether the DNA binding activities of TAL1 were required to 
cooperate with Lmo2 to cause disease in mice, we generated a cohort of 15 Tal1/Lmo2 
and 11 mutTAL1/Lmo2 bitransgenic mice and monitored the animals daily for 
development of disease. Both Lmo2 transgenic lines were included in the study and both 
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lines cooperated with Tal1 and the DNA binding mutant to accelerate leukemogenesis in 
mice (p<.0001) (Figure 1C). Surprisingly, Tal1/Lmo2 and mutTAL1/Lmo2 transgenic 
mouse lines developed disease with nearly identical kinetics (Figure 1C), in spite of the 
fact that the DNA binding mutant TAL1 transgenic mice develop disease more rapidly 
than wild type Tal1 transgenic mice (O'Neil et al., 2001). Approximately 30% of Tal1 
transgenic mice develop leukemia after a long latency, whereas mutTAL1 mice develop 
disease with a median survival of 215 days (Kelliher et al., 1996; O'Neil et al., 2001). In 
contrast, when Lmo2 is co-expressed with Tal1 or mutTAL1, 100% of the mice develop 
T-ALL-like disease with a median survival of approximately 100 days. No significant 
difference was observed when Tal1/Lmo2 and mutTAL1/Lmo2 survival curves were 
compared (p<0.581). Histopathologic examination of tumors isolated from the 
bitransgenic mice revealed a range of tumor immunophenotypes (Table 1), with tumors 
predominantly containing DN and DP or CD8SP cells observed in both Tal1/Lmo2 and 
mutTAL1/Lmo2 mice (Table 1). This study reveals that Tal1/Lmo2 synergy does not 
require the DNA binding properties of TAL1, suggesting that Lmo2 does not contribute 
to leukemia by enhancing or altering the transcriptional activity of the Tal1/E47 or HEB 
heterodimer.  
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Thymocyte developmental arrest in Tal1/Lmo2 and mutTAL1/Lmo2 mice:  
We have shown that thymic expression of Tal1 or the DNA binding mutant 
results in a decrease in overall thymocyte cellularity due to fewer DP and CD8-positive 
thymocytes (Kelliher et al., 1996; O'Neil et al., 2001). Expression of Lmo2 under the 
control of the proximal lck promoter appeared to have no detectable effects on DP 
thymocyte development (Figure 2B), however Lmo2 expression decreased thymocyte 
cellularity and skewed DN development; although no increases in the absolute numbers 
of DN thymocytes was observed (Figure 2A and C). Consistent with published reports 
(Larson et al., 1996), co-expression of Tal1 and Lmo2 reduces thymic cellularity and 
blocks DP thymocyte development, resulting in increases in the relative and absolute 
number of DN thymocyte precursors in preleukemic Tal1/Lmo2 mice (Figure 2B and D). 
DP thymocyte development was consistently more severely affected in Tal1/Lmo2 mice 
derived from Lmo2 founder (Fo)19 compared to Fo5 (Figure 2B).  
To determine whether the thymocyte developmental block reflects alterations in 
Tal1-mediated gene expression, we examined thymocyte development in 
mutTAL1/Lmo2 pre-leukemic mice. We found thymocyte cellularity futher reduced in 
mutTAL1/Lmo2 mice compared to mice that express the TAL1 DNA binding mutant 
only (Figure 2A). Overall cellularity was similarly reduced in all the Tal1/Lmo2 and 
mutTAL1/Lmo2 mice examined. Similar to the Tal1/Lmo2 mice, DP thymocyte 
development was consistently more severely affected in mutTAL1/Lmo2 mice derived 
from Fo19 compared to founder Fo5 (Figure 2B). Importantly, the DNA binding TAL1 
mutant cooperated with Lmo2 to induce similar effects on thymocyte development as 
wild type TAL1 (Figure 2).  
Expression of Lmo2 with Tal1 or mutTAL1 also altered DN thymocyte 
development, resulting in arrest at the DN3-DN4 precursor stage (Figure 2C and D). In 
contrast, an E2A or HEB deficiency results in an arrest of DN thymocyte development at 
the DN1 and DN3 stages, respectively (Bain et al., 1997; Greenbaum and Zhuang, 2002a; 
Greenbaum and Zhuang, 2002b). These studies demonstrate that Lmo2 does not require 
the DNA binding properties of TAL1 to perturb thymocyte development. The block in  
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thymocyte development induced by either form of Tal1 is not complete, as DP and SP 
thymocytes are detected (Figure 2C). Moreover, immunophenotyping of Tal1/Lmo2 and 
mutTAL1/Lmo2 tumors revealed that tumors from both bitransgenic lines were often 
heterogeneous, consisting of DN and DP and/or CD8 SP cells (Table 1). For example, 
although the primary Tal1/Lmo2 tumor 5338 is clonal, it contains DN, DP and CD8-SP 
cells, suggesting that differentiation proceeds at some level after leukemic 
transformation.  
The expression of E47/HEB-regulated genes is decreased in both Tal1/Lmo2 and 
mutTAL1/Lmo2 mice.  
To understand how Lmo2 can cooperate with a DNA binding mutant of TAL1 
and interfere with thymocyte development, we examined the expression of E47/HEB 
target genes known to regulate thymocyte differentiation. Previously, we found the 
expression of PreTα, Rag1/2, CD3 CD4, T cell receptor α/β and CD5 repressed in the 
presence of the Tal1 oncogene (O'Neil et al., 2004). The expression of these thymocyte 
differentiation genes was further decreased in Tal1/E2A+/- or HEB+/- mice, indicating 
that Tal1 alters thymocyte development by interfering with the transcriptional activities 
of the E47/HEB heterodimer (O'Neil et al., 2004). Using real time PCR, we quantified 
the expression of the immunoglobulin and T cell receptor gene recombinases Rag1 and 
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Rag2 and the pre-Tα chain of the pre-TCR. We found the expression of Rag1 and Rag2 
significantly decreased in Tal1 and mutTAL1 preleukemic thymocytes (Figure 3). Slight 
decreases in Rag1/2 expression were also detected in the Lmo2 transgenic thymus, 
although no gross perturbations in the thymocyte developmental profile were observed. 
Co-expression of Tal1 or its DNA binding mutant with Lmo2 resulted in consistent 
further decreases in Rag1 and Rag2 expression (Figure 3). Similarly, we found preTα 
expression further repressed in preleukemic Tal1/Lmo2 or mutTAL1/Lmo2 thymocytes 
than in thymocytes expressing Tal1, mutTAL1 or Lmo2 alone (data not shown). The 
reduced expression of these E47/HEB-regulated genes does not reflect changes in the 
relative percentage of DN vs DP stage thymocytes, as significant decreases in Rag1/2 and 
PreTα gene expression were observed in Tal1 and mutTAL1 animals, where the 
thymocyte developmental profile is only modestly altered (Figure 2B). These data reveal 
that in the presence of Tal1 and importantly, a DNA binding mutant of TAL1, Lmo2 
expression results in further reductions in E47/HEB transcriptional activity. These 
findings suggest that Lmo2 binding to Tal1 or mutTAL1/E47 or HEB heterodimers may 
stabilize the Tal1/E47 or HEB complex, resulting in greater E47/HEB sequestration.  
Consistent with our in vivo data, the binding affinities for the Tal1/E47 
heterodimer have been measured in vitro and shown to significantly increase in the 
presence of Lmo2 (KA of ~ 4 X 107 vs KA of ~ 1 X 108)(Ryan et al., 2008). Therefore, 
Lmo2 binding appears to increase the affinity of Tal1 for E47 or HEB and this interaction 
is greater than the affinity of Lmo2 for its LIM domain binding partner, Ldb1 (KA of 5 X 
107) (Ryan et al., 2008). These estimates predict that E protein sequestration may be 
favored in a setting where Tal1 and Lmo2 are both expressed. 
Our findings have therapeutic implications and suggest that interfering with 
Tal1/E47 or Tal1/Lmo2 binding may release E47/HEB proteins and stimulate leukemic 
cell differentiation and/or apoptosis. Disrupting a large protein interface such as a helix-
loop helix interaction with small molecules may not be feasible. However, in some 
instances, only a minor part of the protein dimer interfaces contribute to the affinity  
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between proteins (Clackson and Wells, 1995; Kussie et al., 1996; Wells, 1996; Wells and 
de Vos, 1996). Targeting these regions may be sufficient to inhibit protein:protein 
interactions. Small molecules have in fact been identified that interfere with the 
Myc/Max bHLH/LZ interaction and these molecules have been shown to interfere with c-
Myc-induced transformation in vitro (Berg et al., 2002). Alternatively, interfering with 
Lmo2 binding to Tal1 may be sufficient to induce apoptosis of T-ALL cells. Retroviral 
expression of an anti-Lmo2 single chain Fv antibody fragment or an Lmo2 aptamer have 
been shown to reduce leukemic growth in transplanted mice (Nam et al., 2008), 
suggesting that interfering with LMO2 protein interactions may be an effective 
therapeutic strategy for some relapsed T-ALL patients. 
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Materials and Methods: 
Generation of transgenic mice: Murine Lmo2 cDNA was cloned into p1017, a plasmid 
containing the proximal lck promoter and the human growth hormone splice and poly 
adenylation addition sites. The plasmid DNA was sequenced and digested with SpeI for 
microinjection into the FVB/N pronuclei. Transgenic founders were identified by 
Southern blotting and mated with FVB/N mice.  
Cell culture and flow cytometry: Mouse T-ALL tumors were minced into a single-cell 
suspension using frosted slides and cultured in RPMI with 10% fetal bovine serum, l% 
glutamine, penicillin/streptomycin, and 50 μM β-mercaptoethanol at 37°C under 5% 
CO2. Thymi from preleukemic mice were gently disrupted with frosted glass slides in 
order to produce single cell suspensions. The thymocytes were washed with PBS and 
stained with fluorescent labeled antibodies and subjected to flow cytometry at the FACS 
facility at the University of Massachusetts Medical Center. For double negative analysis, 
cells were stained with antibodies for the lineage antibodies, and the lineage negative 
cells were stained with CD44-APC and CD25-Fitc. Antibodies used in flow cytometry 
included CD3-PE, CD4-PE, CD4-Cy5 PE, CD8- FITC, CD8-Cy5-PE, CD25-Fitc, CD44-
APC, and lineage markers (Pharmingen). Data were analyzed using FlowJo software 
(Treestar, Inc.). For tumor immunophenotyping, primary tumors cells were stained with 
either PE or FITC-conjugated anti-mouse Ly-2 (CD8), L3T4 (CD4), CD25, and CD3 
antibodies (BD Pharmingen, San Diego, CA, USA), and analyzed by flow cytometry. 
Quantitative PCR: RNA was extracted from primary thymocytes using Trizol. cDNA 
was synthesized using the Superscript first-strand synthesis system (Invitrogen). Rag1, 
Rag2, and pre-Tα expression was assayed using primers as described in reference (Hsu et 
al., 2003; Huang et al., 2003). To determine target gene expression levels, cDNA was 
serially diluted and quantified using the SYBR green kit (QIAGEN) gene-specific 
primers and β-actin specific primers using relative quantification analysis.  
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Abstract: 
Gain of function mutations in NOTCH1 are frequently detected in patients with T 
cell acute lymphoblastic leukemia (T-ALL) and in mouse models of the disease.  
Treatment of mouse or human T-ALL cell lines with γ-secretase inhibitors (GSI) to 
inhibit Notch1 activity in vitro results in growth arrest and apoptosis.  These studies 
reveal GSI as potential therapeutic agents in the treatment of T-ALL.  To determine 
whether GSI have anti-leukemic activity in vivo, we treated near end stage 
tal1/ink4a/arf+/- leukemic mice with vehicle or with a GSI developed by Merck Research 
Laboratories (MRK-003).  We found that GSI treatment significantly extended the 
survival of leukemic mice, when compared to vehicle treated mice.  Notch1 target gene 
expression was repressed and increased numbers of apoptotic cells were detected in the 
thymic masses isolated from the GSI treated mice.  This study demonstrates that Notch1 
activity can be successfully inhibited in vivo when administered as a single agent to mice 
with advanced disease, GSI treatment prolongs survival.  This work supports the idea of 
targeting NOTCH1 in the treatment of T-ALL patients.   
Introduction: 
T cell acute lymphoblastic leukemia (T-ALL) is associated with the mis-
expression of the basic helix-loop-helix transcription factor TAL1/SCL and LIM-domain 
only proteins LMO1 and LMO2 (Aplan et al., 1991; Aplan et al., 1992; Bash et al., 1995; 
Bernard et al., 1991; Boehm et al., 1991; Brown et al., 1990; Royer-Pokora et al., 1991).  
These oncogenes are found mis-expressed in greater than 60% of human T-ALL patients 
(Bash et al., 1995; Ferrando et al., 2004; Ferrando and Look, 2003).  Mouse models of T-
ALL recapitulate the disease through ectopic expression of Tal1 in the thymus (Kelliher 
et al., 1996). These mice develop respiratory distress due to the presence of large thymic 
massess and have detectable T cell blasts in peripheral blood lymphocytes (PBL), spleen, 
liver, and kidney (Kelliher et al., 1996; Shank-Calvo et al., 2006).  Mis-expression of 
Tal1 results in perturbed thymocyte development by interfering with the basic-helix-loop-
helix (bHLH) heterodimer E47/HEB that regulates the expression of genes critical for 
thymocyte differentiation including rag1/2, pre-Ta, CD4,CD3, TCRa/b (Herblot et al., 
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2000; O'Neil et al., 2001; O'Neil et al., 2004).  Consistent with this finding, loss of the 
E2A gene that encodes the E47/E12 bHLH protein is associated with human T and B cell 
leukemias (Mullighan et al., 2007). 
Mutations in the Notch 1 receptor have been frequently detected in mouse T-ALL 
models (Dumortier et al., 2006; Lin et al., 2006; O'Neil et al., 2006; Reschly et al., 2006) 
and importantly in 54% of T-ALL patients (Grabher et al., 2006; Weng et al., 2004). 
These mutations cluster in the heterodimerization domains (HD) or result in truncation of 
PEST regulatory sequences (O'Neil et al., 2006; Weng et al., 2004).  Mutations in the HD 
result in increased susceptibility to cleavage by the gamma-secretase complex, whereas 
deletion of PEST regulatory sequences results in increased Notch1 stability (Gupta-Rossi 
et al., 2001; Malecki et al., 2006; Sanchez-Irizarry et al., 2004).  Treatment of mouse tal1 
leukemic cell lines in vitro with gamma secretase inhibitors (GSI) results in cell cycle 
arrest and apoptosis, revealing that Notch1 signaling is required for leukemic 
growth/survival (O'Neil et al., 2006). Notch1-mediated leukemic growth in mouse and 
human T-ALL cells is mediated in part by the direct transcriptional activation of c-myc 
(Palomero et al., 2006; Sharma et al., 2006; Weng et al., 2006).  Similarly, Notch1 
mediated mammary tumorigenesis in the mouse also appears c-myc dependent (Klinakis 
et al., 2006).   It remains unclear, however, whether c-myc expression is required for 
Notch1-mediated leukemogenesis or whether other Notch1 target genes contribute.  
Although the majority of mouse tal1 leukemic cell lines undergo apoptosis upon 
GSI treatment in vitro, it is unclear whether Notch1 can be inhibited for extended periods 
of time in vivo.  An additional concern regarding targeting Notch1 in T-ALL is that in 
contrast to mouse, human T-ALL lines appear relatively GSI resistant in vitro, raising the 
possibility that GSI alone may not prove effective in the treatment of T-ALL patients.  
Moreover, whether GSI can be administered in vivo for extended periods of time without 
associated toxicities remains uncertain.   
In this study, we examine the effects of GSI treatment in our mouse T-ALL 
model.  To examine GSI efficacy and to accurately reflect the clinical experience, we 
treated near end stage leukemic mice and found that GSI treatment extends the survival 
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of leukemic mice, but is not sufficient to eliminate disease.  Collectively, this work 
supports the idea of targeting NOTCH1 in the treatment of T-ALL.  
Results: 
The GSI MRK-003 represses Notch1 target gene expression and induces apoptosis of 
mouse T-ALL cell lines and primary tal1/ink4a/arf+/- tumors. 
The prevalence of mutations that result in activated NOTCH1 in T-ALL patients 
raises the possibility that GSI used to inhibit Notch1 and other GS-dependent substrates 
in vitro may have anti-leukemic activity in the clinic. GSI have been developed by Merck 
Research Laboratories, Inc yet their ability to inhibit Notch1-mediated mouse leukemic 
growth was untested (Lewis et al., 2007; Sparey et al., 2005). To test whether MRK-003 
inhibited Notch1, multiple mouse T-ALL cell lines were treated with 1mM or 10mM of 
MRK-003 and Notch1 target gene expression examined. Decreased levels of hes1 and 
deltex expression were observed in the MRK-003 treated cultures following treatment for 
24 hours (Figure 1A).   
We then compared the relative effectiveness of MRK-003 with DAPT, another 
GSI known to inhibit mouse leukemic growth (O'Neil et al., 2006). Multiple mouse T-
ALL cell lines were treated with 1mM MRK-003 or with 1mM of DAPT for three days 
and cell cycle analysis performed.  In all three of the cell lines tested, increases in the 
percentage of apoptotic cells was observed in MRK-003 treated cultures.  In cell line 
5151, DAPT treatment failed to induce apoptosis above background levels, whereas 58% 
apoptotic cells were detected in the MRK-003 treated cultures (Figure 1B).  This in vitro 
data suggested that MRK-003 may be effective at inhibiting Notch1-mediated leukemic 
growth in vivo.  However, tumor adaptation to culture clearly involves the accumulation 
of additional genetic changes and therefore, in vitro GSI responses using mouse or human 
T-ALL cell lines may not accurately predict GSI efficacy in vivo.   
To test whether MRK-003 might be effective against primary tumors harboring 
spontaneous notch1 mutations, thymic tumor masses isolated directly from tal1/ink4a/arf 
+/- mice were treated with vehicle only, with 1mM DAPT or 1 mM MRK-003 for three 
days. The percentage of apoptotic cells was then determined by Annexin V/PI staining 
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followed by flow cytometry. As expected, apoptotic cells (32.4%) were observed in the 
DMSO or vehicle treated cultures over the three day culture period.  DAPT treatment, 
however, increased the percentage of apoptotic cells to approximately 62.2 % (29.8% 
increase), whereas the MRK-003 treated cultures contained 88.8% Annexin V/PI-positive 
cells (56.4% increase). Although apoptosis varied among the 3 primary tumors tested in 
this assay, the trend remained the same. 
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GSI treatment prolongs survival in a mouse T-ALL model 
These ex vivo studies indicated that MRK-003 administration to leukemic mice 
might induce apoptosis in vivo, decrease tumor burden, and increase overall survival. To 
test this possibility, we treated mice daily with 50 mg/kg, 200 mg/kg, or 1000 mg/kg 
MRK-003 and determined plasma concentrations of the compound. We found that 
effective plasma MRK-003 concentrations (1-10 µM) were achieved in mice treated with 
all 3 doses (Figure 2A). However, when the MRK-003 compound was given daily at 150 
mg/kg, the mice began to develop diarrhea and lose weight (Figure 2C; R1 compared with 
V). Chronic GSI administration is known to result in gastrointestinal (GI) toxicity due to 
Notch inhibition in the intestinal epithelium, resulting in gut metaplasia. To assess GSI 
efficacy on mouse leukemic growth, we adopted an intermittent GSI dosing regimen that 
achieved effective concentrations of the drug without associated toxicities. Specifically, 
mice treated with 150 mg/kg MRK-003 for 3 days followed by a 4-day rest period had 
effective plasma compound levels (Figure 2B), did not lose body weight (Figure 2C, 
mouse R2), and exhibited limited gut metaplasia. MRK-003 plasma levels peak after 
administration and effective drug concentrations are detected at 24 hours after treatment. 
In addition, in a preclinical mouse model, this intermittent dosing schedule was well 
tolerated, as no evidence of intestinal effects were detected after a 35-day treatment 
period. In an attempt to accurately reflect the clinical experience, near-end-stage leukemic 
days followed by a 4-day recovery period. After the 3 days of GSI treatment, plasma 
compound levels were determined and an EC50 of 5 to 10 µM MRK-003 was achieved 
(data not shown). Leukemic mice were treated with vehicle or MRK-003 after the 3 days 
on, 4 days off treatment regimen throughout the duration of the study. We found that GSI 
treatment resulted in a statistically significant increase in overall survival of leukemic 
mice compared with vehicle-treated mice (Figure 2D; P < .005). The median survival 
period for GSI-treated mice was 18 days compared with 3 days for the vehicle-treated 
group. In most cases, responses were evident in the MRK-003–treated mice immediately 
after the 3-day treatment period, as measured by an increase in physical activity and 
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improved rates of respiration. Importantly, body weights are maintained in MRK-003–
treated animals after successive cycles of intermittent GSI dosing. This pilot study 
supports the idea that GSI-associated toxicities may be overcome with intermittent dosing 
and provides evidence that Notch1 inhibition improves mouse leukemic survival in vivo. 
GSI treatment induces apoptosis of leukemic cells in vivo 
To determine whether GSI treatment induces apoptosis in vivo, we performed 
TUNEL staining on thymomas isolated from vehicle- or GSI-treated mice. We detected 
increases in the percentage of apoptotic tumor cells in mice treated with MRK-003, 
compared with tumors exposed to vehicle only (Figure 3A-B; P = .034 by Wilcoxon rank 
sum test). However, similar to our in vitro data (Figure 1B and (Sharma et al., 2006), the 
in vivo tumor response to GSI was variable. Three of the 4 GSI-treated mice examined 
exhibited an increase in apoptotic leukemic cells, with 2- to 10-fold increases in TUNEL+ 
tumor cells observed (Figure 3B). An increase in TUNEL+ cells was not observed in 1 of 
4 tumors from the GSI-treated group (mouse 6448). However, we were unable to detect a 
Notch1 mutation in this tumor. The reasons for the variable GSI responses both in vitro 
and in vivo are unclear. One possibility for the variable in vivo responses may be that 
some tumors require longer treatment periods. For these studies, leukemic mice were 
treated with vehicle or with GSI for 3 days and then the mice were humanely killed and 
tumor sections analyzed for the presence of apoptotic cells. It is conceivable that more 
consistent responses may be observed in leukemic mice treated with multiple GSI doses. 
Nonetheless, GSI treatment clearly induced apoptosis and extended the survival of 
leukemic mice. 
Transient GSI responses do not reflect development of GSI resistance 
One potential reason for variable responses may be that the GSI treated mice 
develop GSI resistance.  To exclude this possibility, T-ALL cell lines were generated 
from the GSI and vehicle treated mice and their response to GSI quantified in vitro.  As 
expected, truncated Notch1 proteins were detected in both vehicle and GSI treated mice 
and GSI treatment significantly reduced Notch1 protein levels (Figure 4A).  Leukemic 
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cell lines also clearly remained dependent on Notch1 for growth, as G1 arrest and 
apoptosis was observed upon GSI treatment (Figure 4B).  These findings indicate that 
transient responses to GSI in vivo do not reflect the development of GSI resistance.  
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Repression of Notch1 target gene expression in GSI treated mice 
To further understand why GSI treatment prolonged survival but failed to 
eliminate disease, we examined Notch1 target gene expression using real time PCR in the 
vehicle and GSI treated leukemic cohorts.  We found hes1 expression reduced in MRK-
003 treated leukemic mice compared to mice that received vehicle only (Figure 5).  The 
levels of hes1 repression were similar to levels observed when the leukemic cell line 720 
is treated with GSI in vitro.   
Discussion: 
The prevalence of NOTCH1 and FBW7 mutations in human T-ALL (O'Neil et 
al., 2006; O'Neil et al., 2007; Thompson et al., 2007; Weng et al., 2004) and in mouse T-
ALL models (Dumortier et al., 2006; Lin et al., 2006; O'Neil et al., 2006) prompted 
several laboratories to ask whether leukemic growth remained NOTCH1-dependent.  GSI 
treatment of mouse and human T-ALL cell lines and primary mouse tumors expressing 
mutated Notch1 proteins (Figure 1C) revealed that sustained Notch1 signals appear 
required for continued growth and survival in vitro  (Lewis et al., 2007; O'Neil et al., 
2006; Palomero et al., 2006; Sharma et al., 2006; Weng et al., 2004; Weng et al., 2003).  
These findings raised the exciting possibility that Notch1 inhibition may prove effective 
in treating T-ALL patients and led to the opening of a phase 1 clinical trial on 8 relapsed 
leukemia and lymphoma patients.  However, the trial closed due to significant dose 
limiting toxicities with the critical question regarding GSI efficacy in T-ALL 
unanswered.  
To address this question, we examined the effect of GSI treatment in our mouse 
T-ALL model where the effects of Notch1 inhibition could be addressed on primary 
tumors opposed to relapsed disease (and where microenvironmental influences remained 
intact). Seventy four percent of tal1/ink4a/arf+/- transgenic mice develop a T-ALL like 
disease due to mutations that result in premature truncation of the Notch1 receptor 
(O'Neil et al., 2006).  To determine whether Notch1 can be targeted in vivo, we needed to 
develop a GSI dosing regimen that minimized the ‘on target’ gastrointestinal (GI) toxicity 
associated with Notch1 inhibition.  We determined that intermittent GSI dosing 
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(150mg/kg three days on and four days off) reduced the GI toxicity and then tested 
whether this regimen had any effect on the survival of leukemic tal1/ink4a/arf+/- mice.  
We found that GSI treated mice 
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survived on average 15 days longer than leukemic mice treated with vehicle only.  
Notch1 target gene expression (hes1 and c-myc) was repressed and increased numbers of 
apoptotic cells were detected in the thymic masses of diseased mice treated with GSI.  
These data support the idea that Notch can be successfully targeted in vivo and that 
treatment with GSI as a single agent has efficacy and extended the survival of leukemic 
mice. 
Despite the expression of other T-ALL associated oncogenes such as tal1/scl and 
lmo1/2 and the loss of tumor suppressors (ink4a/arf, pten), mouse T cell leukemic growth 
appears preferentially ‘addicted’ to the Notch1 proliferative signal(s).  Although GSI 
treatment significantly increased the overall survival period, it was not sufficient to cure 
the mice and 100% of the GSI treated mice eventually succumbed to disease.  The 
transient GSI response was not due to the development of GSI resistance, as all mouse 
tumors tested remained GSI responsive when re-examined in vitro.  One possibility is 
that the transient response to GSI may reflect the intermittent dosing regimen and long 
term suppression of Notch1 activity may require more frequent GSI administration. 
Alternatively, chronic GSI treatment may promote reliance on other growth and survival 
pathways.  For example, Gleevec administration to mice with CML-like disease shifts the 
reliance from activated ABL towards a greater dependence on the IL-7 signaling pathway 
(Williams et al., 2006). Both studies highlight the importance of examining drug efficacy 
in mouse models that maintain the appropriate microenvironment.   
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Although the results from this mouse GSI study are promising, human T-ALL cell 
lines are far less responsive to GSI treatment in vitro (Lewis et al., 2007; Weng et al., 
2004).  Even at increased concentrations and extended incubation periods (>10days), 
little evidence of cell death is observed when human T-ALL cell lines or primary 
leukemic samples are treated with GSI (Lewis et al., 2007; Palomero et al., 2006; Weng 
et al., 2004). These findings cast doubt as to whether GSI or other Notch1 inhibitors will 
be effective in T-ALL patients.  Additionally, an effective GSI dose with minimal 
toxicity may be difficult to achieve in patients.  In fact, we found the response of GSI 
strain dependent, raising the possibility that genetic background may influence patients 
GSI responses (Pradip Majumder, unpublished data or personal communication).   
Materials and Methods: 
Mouse T-ALL Cell Lines  
Murine leukemic cell lines were cultured in RPMI with 10% FBS, 1% glutamine, 
Penicillin/ Streptomycin, 50μM β-mercaptoethanol at 37°C under 5% CO2.  To inhibit 
Notch1 signaling, cells were plated at 1x106 in a 10cm dish in the presence of either 
MRK-003 (Merck Research Laboratories, Inc.,). Mock-treated cells were cultured with 
DMSO at a final concentration of 0.01%. 
GSI efficacy studies  
A cohort of tal1/ink4a/arf +/- transgenic mice was generated (n= 30) and monitored daily 
for the onset of leukemia as described previously (Shank-Calvo et al., 2006).   Once 
disease became evident (respiratory distress, inactivity, weight loss) leukemic 
tal1/ink4a/arf +/- mice were randomly assigned to the vehicle or GSI treatment groups 
(vehicle cohort n=14, GSI cohort n=16).   Leukemic mice were administered either a 
150mg/kg dose of freshly prepared MRK-003 (dissolved in 0.5% methylcellulose) or a 
comparable volume of 0.5% methylcellulose by oral gavage.  Mice were treated for three 
consecutive days followed by a rest period of four days. Mice were euthanized when 
deemed moribund by a third party blinded to the treatment group. Survival data was 
plotted using Kaplan-Meyer survival curves and statistical analysis performed using 
SPSS software.  
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TUNEL staining 
Paraffin embedded tumor sections were analyzed for apoptosis using the ApopTag Plus 
peroxidase TUNEL kit (Chemicon, Temecula, CA). Approximately, 10 fields from each 
slide were counted and compared to the serial section not treated with the TdT enzyme.  
Flow cytometry 
Mouse leukemic cells were pelleted by centrifugation for 10 minutes at 2000 rpm, 
washed in PBS, and resuspended in 70% ice-cold ethanol. Cells were fixed overnight and 
then stained with propidium iodide. DNA content was analyzed by flow cytometry 
(FACScan) (BD Biosciences, San Jose, CA). Data was analyzed using FlowJo version 
7.0 (Tree Star, Ashland, OR). Following GSI or vehicle treatment for three days, primary 
thymic masses isolated directly from tal1 transgenic animals were stained with FITC-
Annexin V/PI and analyzed by flow cytometry (BD Biosciences, San Jose, CA). 
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